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Cancer is an often devastating disease that affects populations throughout the 
world.  The major cause of cancer-related death is metastasis, not the primary tumor.  By 
understanding changes in cancer cells that allow them to locally invade and move into 
new tissues and organs, we may be able to identify new therapeutic targets for preventing 
metastasis.  In this work, we approached studying aggressive breast cancer by examining 
how neoplastic cells use energy.  We hypothesized that alterations in metabolism may 
define a switch that causes cancer cells to change their behavior from a highly 
proliferative state, like that of a primary tumor, to a more motile and invasive state, 
leading to the early steps of metastasis.   
We found that inhibition of the mevalonate pathway, a metabolic pathway that 
makes cholesterol and isoprenoid precursors for the lipid bilayer as well as hormone 
precursors for signaling, leads to decreased motility and invasion in breast cancer cells.  
In addition, we identified an alternative mechanism for mevalonate inhibitor, zoledronic 
acid. 
 Studying the metabolic switch from a different perspective, we found that the rare 
and highly aggressive inflammatory breast cancer cell line SUM149 does not undergo 
oxidative phosphorylation.  Rather, these cells use an alternative metabolic pathway to 
direct acetyl-CoA out of the tricarboxylic acid cycle, thereby preventing the production 
of oxidative phosphorylation intermediates.  This pathway may enable these cells to 
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survive more readily in conditions of hypoxia, because oxidative phosphorylation, which 
consumes oxygen, would be unnecessary.  
 Finally, returning to our overall aim, we examined the behavioral switch between 
proliferation and motility directly by investigating an aggressive breast cancer cell line 
MDA-MB-231 in which we had knocked down mitogen activated protein kinase pathway 
member p38gamma.  This results in highly proliferative, but less motile cells. We 
performed unbiased metabolomic screening and found that nucleotide synthesis, NADH 
metabolism, and C-21 steroid hormone biosynthesis are necessary for this change in 
behavior. From this work, we learned how individual metabolic pathways may regulate 
motility and invasion.  Characterizing how these pathways interact to create the ideal 
environment to induce cancer cells to become metastatic will be the focus of discussion 






Metastasis of cancer cells is the cause of most cancer-related deaths[1].  
Excluding basal and squamous skin carcinomas, breast cancer is the most common 
cancer in women, and the 2nd most deadly in terms of number of deaths per year[1].   
Breast cancer normally follows a progression from the formation of a primary tumor, to 
secondary metastases principally to the bone, brain, liver or lung, if the primary tumor is 
not treated or eliminated before metastases form.  In a primary tumor, cellular 
proliferation is very important for the tumor to gain its bulk mass.  After a period of time, 
due to mechanisms not yet fully understood, tumor cells then regain or acquire the ability 
to move away from the primary tumor to a new area in the body.  At this point, metabolic 
energy use is channeled mainly towards movement and invasion, instead of proliferation.  
Understanding the switch of energy use from proliferation to motility is crucial to 
understanding the molecular mechanisms of metastasis and a step toward the prevention 
of metastasis.  This work focuses on the transition between proliferation and motility and 
thus on the metabolic changes that occur in cancer as well as on the motility processes 
involved in metastasis.  
This chapter will cover the known alterations of metabolism in cancer cells and 
changes in motility that allow cancer cells to leave their initial location and invade the 
surrounding tissue and eventually metastasize.   
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Review of Cancer Cell Metabolism 
Energy utilization is an important process in every living cell.  Metabolic 
processes regulate cell growth, division, movement, and death.  Alterations in metabolic 
pathways have been shown to both enable and cause cancer formation.  One of the first 
experiments in this field was led by Otto Warburg in the 1920s.  He showed that cancer 
cells use anaerobic metabolism even when sufficient oxygen was present[2].  This 
behavior was later named “The Warburg Effect”.  Warburg’s pioneering work fell by the 
wayside with the discovery of new viral causes of cancer (such as Peyton Rous’s 
discovery of tumor viruses in chickens) and genetic alterations called oncogenes[3]. The 
differences observed in the metabolism of cancer and non-cancer was not widely studied 
again until the late 1970s, when increased glucose uptake by cancer cells was discovered 
to be a useful diagnostic tool in the clinic [4, 5]. Since then, scientists have been working 
to discover why cancer cells use aberrant metabolism and how these changes might be 
manipulated to improve cancer therapy.  Besides decreased oxidative metabolism and 
increased lactate production, a variety of specific metabolic changes are observed in 
cancer cells.  
Cancer cells take up more substrates, or do so more rapidly, than normal cells 
Increased nutrient and growth factor uptake by cancer cells is part of the process 
that allows them to grow faster than normal cells and also allows them to outcompete 
surrounding cells for nutrients and growth factors.  Tumors express greater numbers of 
glucose transporters, known as GLUT proteins on the outside of their cells[6]. They also 
overexpress a variety of growth factor receptors[7].  The increased uptake and utilization 
of glucose in cancer cells is sufficiently different from normal cells that it can be used as 
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a diagnostic tool to identify areas of cancer in the body.  In Positron Emission 
Tomography (PET) scans, a radiolabeled glucose analog 2-fluoro-2-deoxy-D-glucose 
(18FDG) is given to the patient.  18FDG can be taken up by the cells via the glucose 
transporters with the same efficiency of glucose, but because of the lack of the hydroxyl 
group at the 2-position, it is unable to become further metabolized by hexokinase, the 
first glycolysis enzyme.  18FDG remains in the cell long enough to radioactively decay, 
producing an image.  Areas where the 18FDG accumulates are likely to be areas of high 
metabolic activity and are most likely (but not exclusively) cancerous.  The uptake of 
glucose by clinical tumors can be up to an order of magnitude higher than in normal cells, 
allowing accurate and efficient diagnosis of the presence of metabolically active lesions 
by PET scanning.[8] Glucose uptake has been shown to correlate with tumor 
aggressiveness and prognosis in breast cancer, making PET diagnosis a very valuable 
tool in widespread use for predicting the outcome of breast tumors and response to 
therapy in some cases.[5, 9] 
Glycolysis is often altered in cancer 
Glycolysis is the main pathway used to break down glucose to pyruvate for entry 
into tricarboxylic acid (TCA) cycle and oxidative phosphorylation (Figure I.1, I.2).  
Pyruvate kinase is an important irreversible step in glycolysis that catalyzes the reaction 
that produces pyruvate from phosphoenolpyruvate (Figure I.2).  The gene which encodes 
this enzyme is alternatively spliced in cells, resulting in tissue specific isoforms of 
pyruvate kinase. The L-isoform of pyruvate kinase (PKL) is expressed primarily in liver 
and kidney tissue, the R-isoform (PKR) is expressed in red blood cells, while the M-
isoforms, PKM1 and PKM2 are expressed in muscle tissues. PKM2 is the embryonic 
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form and is important for development, whereas PKM1 is found predominantly in adult 
tissue [10].  Isoforms PKL, PKR, and PKM1 all can form a stable homotetramer; 
however, PKM2 can form both homotetramers and unstable homodimers.  In cancer, 
embryonic PKM2 is often expressed instead of PKM1. PKM2 differs from PKM1 by 23 
amino acids within a 56 amino acid stretch.  This sequence difference alters the 
secondary and tertiary structure sufficiently that it prevents PKM2 from being stabilized 
in its normal tetramer form by the glycolysis metabolite fructose-1, 6-bisphosphate (FBP) 
[11].  As a result, PKM2 forms dimers instead of tetramers, and the dimeric complexes 
are much slower at catalyzing the reaction of phosphoenolpyruvate (PEP) to pyruvate.  
This, in turn, allows PEP to accumulate, allowing upstream metabolites to be available to 
be redirected through the pentose phosphate pathway to relieve this excess (Figure I.1).   
The pentose phosphate pathway is a major source of nucleotide synthesis, so increased 
flux through this pathway increases the rates at which nucleotides are made for 
replication.  Additionally, PKM2 has been shown to promote serine synthesis [12].  
Serine is known to activate PKM2 allosterically [13], increasing catalytic rate of PKM2 
[12].  When low amounts of serine are present, PKM2 activity is low, and intermediates 
upstream in the glycolysis pathway accumulate.  In response to low serine levels, the 
general control nonderepressible 2 kinase-activating transcription factor 4 (GCN2-ATF4) 
pathway is activated.  This pathway then upregulates serine synthesis enzymes via the 
AT4 transcription factors.  Glycolysis pathway intermediates can be used directly in 
serine synthesis, leading to an increase in serine levels in the cell.  With more serine 
present, PKM2 can be activated such that more glycolysis proceeds forward and lactic 
acid is produced [12].  Additionally, serine is an important amino acid required for 
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protein, nucleotide and lipid synthesis, so increasing serine amounts in the cell will help 
the cell to proliferate more quickly[14]. 
Alterations in the regulation of the glycolysis enzyme phosphofructokinase (PFK) 
have also been identified in cancers.  PFK is responsible for catalyzing the reaction of 
fructose-6-phosphate to fructose-1,6-bisphosphate (Figure I.2).  This reaction is 
irreversible under physiological conditions and represents the first committed step in 
glycolysis, making it very important in the regulation and flux of glucose entering this 
pathway[15]. PFK is inhibited by adenosine-5’-triposphate (ATP), so that when high 
levels of ATP are present, little glucose enters glycolysis.  However, PFK is activated by 
a metabolite not found in the glycolysis pathway, fructose -2, 6-bisphosphate. This 
activation is able to overcome inhibition by ATP. Fructose -2, 6-bisphosphate also 
potently inhibits the gluconeogenic enzyme known as fructose-1, 6-bisphosphatase 
(F1,6BPase), thereby preventing gluconeogenesis from occurring (Figure I.4).  The level 
of fructose -2, 6-bisphosphate in the cell is maintained by a bifunctional enzyme family 
called 6-phosophfructo-2-kinase/fructose-2, 3-bisphosphatases (PFKFB), which 
phosphorylate fructose-6-phosphate to fructose-2, 6-bisphosphate and do the reverse 
dephosphorylation as well.  PFKFB is encoded by a gene that is alternatively spliced 
resulting in four isoforms, termed PFKFB 1-4.  Isoform PFKFB3 is highly overexpressed 
in cancer tissues and has reduced phosphatase activity compared to its kinase activity, 
which results in much higher amounts of intracellular fructose-2,6-bisphosphate in 
certain cancers [15].  This enables the cancer cells to turn glycolysis on via almost 
constitutive PFK activation even when ATP is at high levels within the cell.  Next, I will 
describe the processes cancer cells use to make ATP. 
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Cancer cells use lactic acid fermentation preferentially to oxidative phosphorylation to 
produce energy (ATP) 
Under aerobic conditions in normal cells, glucose is metabolized to pyruvate 
through glycolysis and pyruvate is changed to acetyl CoA, which enters the TCA cycle 
and undergoes oxidative phosphorylation (Figure I.1, I.2, I.3).  This process yields a net 
ATP gain of 32-36 molecules of ATP per glucose molecule depending on the type of 
transporter used to bring the substrate into the mitochondria.  Under anaerobic conditions, 
the cell metabolizes glucose to pyruvate through glycolysis, and pyruvate is changed to 
lactic acid via fermentation.  This yields a net of 2 ATP molecules per glucose molecule.  
In cancer cells, however, lactic acid fermentation is performed preferentially to the TCA 
cycle and oxidative phosphorylation even when oxygen is present, yielding a much lower 
quantity of ATP per glucose molecule.  Warburg postulated  that cancer cells must have 
developed a defect in oxidative phosphorylation, leading to their need to undergo 
glycolysis to make their energy, a process he termed “aerobic glycolysis” as cancer cells 
opted for this pathway even when the cellular oxygen concentration was normal.[2] Later 
research showed that most cancer cells do not have a defect in oxidative phosphorylation; 
instead they use glycolysis preferentially over oxidative phosphorylation to convert 
glucose to ATP [16]. The fact that cancer cells use this less efficient way to produce 
energy might, at first glance, seem counterintuitive.  However, some researchers have 
theorized that by increasing the rate of glycolysis, cancer cells can generate ATP more 
rapidly than normal cells, giving them a proliferative advantage[16].  In addition, another 
study showed that utilizing aerobic glycolysis may give cancer cells a survival advantage 
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by protecting them against damage from the reactive oxygen species produced during 
oxidative phosphorylation.[17] 
Mutations of TCA cycle enzymes has been found in some cancers 
Recent work in malignant brain gliomas has found mutations in TCA Cycle 
enzyme isocitrate dehydrogenase genes IDH1 and IDH2.  These mutations decrease the 
ability of isocitrate dehydrogenase to catalyze the conversion of isocitrate to α-
ketoglutarate (Figure I.3).  In addition, this mutation allows isocitrate dehydrogenase to 
convert isocitrate to 2-hydroxyglutarate, which is toxic as it accumulates in the brain, 
thereby increasing morbidity of this disease [18, 19].  In addition, 2-hydroxyglutarate has 
been implicated in the regulation of histone and DNA-methylation, via its inhibition of 
dioxygenases [20].  This suggests that 2-hydroxyglutarate might affect cancer at the 
epigenetic level as well. Other work has shown mutations in fumarase, as well as 
succinate dehydrogenase[21].  These mutations lead to an accumulation of fumarate and 
succinate respectively within the mitochondria.  Recent work show that these different 
TCA cycle mutations may lead to similar phenotypes.  Fumarate and succinate inhibit a 
group of enzymes known as prolyl hydrogenases (PHDs), which are important for 
degrading hypoxia inducible factors (HIFs) [22].  HIF family proteins are very important 
for the cellular response to the stress of low oxygen conditions (hypoxia).  In hypoxia, 
transcription factor HIF-1α activates to a wide array of genes that modify the cellular 
environment in response to lack of oxygen.  For example, glycolysis enzymes are 
upregulated to increase lactic acid fermentation, and angiogenesis (the formation of new 
blood vessels) programs are activated in order to direct oxygen and nutrients to the cells.  
The activation of HIFs is vital to a cancer cells ability to survive hypoxia.  In addition, it 
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may give them a selective advantage to have HIF activated in non-hypoxic situations in 
order to increase access to nutrients and oxygen via angiogenesis and increased 
glycolysis.  Succinate and α-ketoglutarate may also be transported outside of the cytosol.  
Recent work has shown that they interact with a set of orphan receptors, GPR 91 and 
GPR 99, which are G-protein coupled receptors[23].  GPR91 has been shown to play a 
role in neuronal angiogenesis by stimulating vascular endothelial growth factor (VEGF) 
secretion in mice and is activated by succinate[24].  GPR99, being recently discovered, 
has no defined function yet, but has been found to be activated by α-ketoglutarate [23].   
.These receptors react to extracellular succinate and α-ketoglutarate, so the cancer cells 
may secrete these metabolites into the bloodstream to signal to other cells.  As a result, 
these metabolites may act in a way to induce changes in signaling.  Further studies will 
need to be done to understand the impact of these metabolites in signaling.   
TCA cycle intermediates are used for de novo lipid synthesis and nucleotide synthesis 
The TCA cycle intermediates are required for a variety of other metabolic 
processes including lipid synthesis and nucleotide synthesis.  A proliferating cell needs to 
double its cellular contents and DNA, making the production of lipids for cell membranes 
and nucleotides vital.  Citrate can exit the cycle and is converted into acetyl CoA and 
malate via ATP citrate lyase.  This acetyl CoA can then be incorporated into lipid 
synthesis.  In cancer cells, the rate of lipid and nucleotide synthesis is increased, because 
of the increased proliferation rate of these cells.   In particular, ATP citrate lyase as well 
as fatty acid synthase (FSN), responsible for the formation of palmitate from acetyl-CoA 
and malonyl-CoA,  have much higher expression in cancer [25]. Nucleotide synthesis 
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may be higher in cancer due to increased flux of glycolysis intermediates into the pentose 
phosphate pathway via PKM2 inhibition as discussed in the previous sections. 
Glutamine is used as an alternative fuel for the TCA cycle 
Besides providing substrates needed to enter oxidative phosphorylation for ATP 
synthesis, TCA cycle intermediates are also required for fatty acid synthesis and 
nucleotide synthesis.  Because cancer cells need to be able to double their contents in 
order to divide, they need to find another was to keep the TCA cycle running when most 
glucose is being made to generate lactate.  Often, via a process called glutaminolysis, 
cancer cells metabolize glutamine to glutamate, which then can enter the TCA cycle as α-
ketoglutarate.  The use of α-ketoglutarate to replenish TCA cycle intermediates is called 
the anapleurotic or “filling up” reactions because this keeps the TCA cycle active when 
metabolites are exiting the cycle to be used for biosynthetic processes.  Additionally, 
through the process of reductive carboxylation, α-ketoglutarate can be made into citrate 
which can be exported out of the mitochondria for use in fatty acid synthesis. By utilizing 
glutaminolysis to keep the TCA cycle active, the cell can generate the intermediates 
necessary for all of these processes.[26].  
New evidence that cancer cells undergo gluconeogenesis 
Gluconeogenesis is the process by which glucose is produced from other 
substances such as lactate, glycerol, and glucogenic amino acids [27]. This process is 
almost a reverse of glycolysis, with a substitution of a few enzymes which perform 
irreversible reactions in glycolysis (Figure I.4).  When gluconeogenesis occurs in the 
context of strenuous exercise, a situation in which it is necessary to remove lactic acid 
from the muscles during movement and to return it to the muscles as glucose, this process 
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is called the Cori Cycle.   It has been thought for many decades that only cells of liver, 
kidney, and intestinal origin performed gluconeogenesis [27, 28].   However, recent work 
in our lab has shown that cancer cells perform gluconeogenesis as well.  This exciting 
new discovery may jumpstart therapies that may be very effective in tumors not derived 
from liver, kidney, or intestines, as the drugs would have no effect on the tissue 
surrounding the tumor. 
Many metabolic changes as described above occur in cancer cells.  In order to 
understand what role the changing metabolic environment may have on the ability of 
cancer cells to metastasize, a good understanding of motility in the cancer cell context is 
required. The following portion of this chapter reviews the cellular motility, especially in 
the context of cancer cell metabolism.   
Review of Cancer Cell Motility 
Discussion of Cell Movement 
Cell motility is an important process required in normal embryonic development 
and wound healing.  However, in adult, uninjured tissue, this process is abnormal and 
leads to invasion and metastasis of cancer [29].  In order for a cell to move, it must 
polarize, so that the movement machinery is localized in the direction of motion.  To 
initiate movement, breast cells send out protrusions of either lamellipodia or filopodia, 
which are generated via actin polymerization.  Next, new focal adhesions are formed, 
which attach the cell to the surrounding ECM (extracellular matrix) and signaling 
proteins via integrins.  The cell then detaches older focal adhesions in the rear of the cell 
in order to move. 
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An important step for a cell to gain the ability to be motile is the formations of 
protrusions.  These protrusions, either lamellipodia or filopodia,  are tightly regulated by 
Rho proteins (Figure I.5)[30].  Rho family proteins are small GTPase proteins that are 
active when they are bound to GTP and inactive when bound to GDP [31].  Effector 
proteins called GAPs (GTPase activating proteins) and GEFs (Guanosine nucleotide 
exchange factors) aid in the exchange of GTP and GDP bound forms.  GAPs help to 
catalyze the hydrolysis reaction of GTP to GDP, which inactivates the small GTPase 
protein.  GEFs help the small GTPase to exchange its GDP for a GTP, thus activating 
it[31].  In addition GDIs (Guanine nucleotide dissociation inhibitors) bind to the GDP 
bound form of the small GTPase[32].  This prevents nucleotide exchange, thus holding 
the GTPase in an inactive state.  In addition, GDIs prevent the localization of these 
proteins in the membrane by holding small GTPases in the cytoplasm [33].  When these 
proteins are unable to move to the membrane, they cannot direct cell motility by 
regulating protrusion formation.   
The process by which a cancer cell begins to invade and metastasize into 
surrounding tissue is described by the Invasion-Metastasis Cascade [34].  This process 
includes local invasion, intravasation, survival of transport within the vasculature, 
stopping at distant sites, extravasation, survival to form micrometastases, and 
proliferation at new sites (colonization) [34].   
Local Invasion 
In normal mammary development, the milk duct is lined by epithelial cells.  The 
middle of the duct is hollow, allowing space for breast milk to be secreted and stored.  In 
breast cancer, tumors develop within the epithelial cells that line the milk duct [35].  As 
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these tumor cells proliferate, they begin to fill up the hollow area.  Cells in the middle of 
the duct are furthest away from the vasculature and therefore have very limited access to 
nutrients and oxygen from the bloodstream.  This starvation and low oxygen (hypoxic) 
environment induces cell death via necrosis in many of these cells[36].  Eventually, some 
cells acquire the ability to recruit new blood vessels (angiogenesis) by secreting vascular 
endothelial growth factor (VEGF), which induces growth of the vasculature[37].  By 
redirecting the blood supply to support their growth, cancer cells are able to get the 
nutrients they need to grow even faster.  However, once the area can no longer sustain the 
size of the tumor, local invasion begins.  In this process, cells develop the ability to move 
through the epithelial ductal layer and invade into the surrounding stromal tissues.  To 
initiate movement, cancer cells secrete MMPs (matrix metalloproteases) which degrade 
the surrounding matrix, allowing the cells to move between other cells.  To form normal 
tissue, cells express certain adhesion proteins on their cell membranes that allow the cells 
to adhere to their neighbors.  These adhesion proteins, such as β-catenin and e-cadherin, 
are often not expressed by cancer cells.  This allows cancer cells to dissociate from one 
another and invade the surrounding tissue as single cells. When these cell-adhesion 
markers are maintained in a cancer cell, the cells instead can use collective cell motility, 
and form fingerlike projections or clumps that push out into the surrounding stroma [38, 
39].   
Intravasation and survival within the vasculature 
Intravasation is the process by which tumor cells enter the bloodstream and 
lymphatic system in order to metastasize.  Within and around a tumor, blood vessels are 
often leaky due to their quick turnover in the process of angiogenesis, which may enable 
13 
 
cancer cells to enter the bloodstream [37].  Once inside the vasculature, tumor cells need 
to evade the immune system, and withstand the high forces that are generated within the 
blood vessels.  One way that tumors do this is to form emboli, or clusters of cells [40].  
These clusters can secrete factors that attract platelets within the blood to congregate 
around the emboli[41].  The platelets form a cloak that surrounds the emboli and prevents 
the natural killer cells, macrophages, and other immune cells from detecting the cancer 
cell and destroying it[42].   
Stopping at distant sites, extravasation, survival, and proliferation 
Once a cancer cell has survived the bloodstream or within the lymphatic system, it 
must find a new site to go to in the body.  Often cells will lodge themselves in the 
capillary beds where the vessel walls are too small to support the cell cluster[34]. Once 
stopped, the cell must escape from the blood vessel wall.  It is likely that some of the 
features that made it easy for the cell to intravasate such as leaky vessels and less immune 
cell guarding are not present far from the tumor. Some studies suggest that MMP 
secretion as well as the ability of the cell to compress in order to squeeze through gaps in 
the vessel wall are involved in extravasation [43].  Once the tumor cells have escaped the 
vasculature, they must survive and form micrometastases.  Further, it must be able to 
reactivate its proliferative program in order to colonize the new area. The “seed and soil” 
hypothesis proposed in 1889 by Steven Paget,  describes how the seed (metastasizing 
cancer cell) coming from cancer of a particular organ usually forms micrometastases only 
in particular soils (areas of the body)[44].  Different factors such the characteristics of the 
new area as well as available signaling molecules may make a particular area more 
suitable for colonization. For example, studies have shown that the bone has an ideal pH 
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and calcium content to encourage colonization by breast cancer cells.  In addition, 
cytokines and growth factors present in the bone may help metastases grow.  Recent 
studies tracking breast cancer cells from primary tumor to micrometastases show that 
CXCR4 is overexpressed in breast cells that successfully metastasize[45].  CXCR4 is a 
receptor for CXCL12, a chemotactic factor which is expressed in the stromal cells of the 
bone, brain, liver, and lung [46].  Additionally, infliximab, an FDA approved monoclonal 
antibody therapy approved for treating Crohn’s disease is a tumor necrosis factor (TNF)-
α antibody, and has been shown to reduce breast cancer metastasis to bone in a murine 
xenograft model.  This effect was shown to be mediated by a reduction in CXCR4 
expression [47].  The wide expression of CXCR4 in specific tissues is one possible 
explanation for why breast cancer cells form metastases primarily in the bone, brain, 
liver, and lung. 
Causes of metastasis 
 In the literature, theories abound about what causes a tumor to metastasize, but 
the exact mechanism explaining both how and why a tumor cell leaves the primary tumor 
is not known.  Some hypotheses include the development of cellular autonomy, response 
to chemoattractants, exhaustion of local resources, and hypoxia effects.  López-Lázaro 
proposes a model in which the hypoxic environment of the tumor results in increased 
glycolysis leading to secretion of high amounts of lactic acid.  This helps to aid the tumor 
in acidifying the area around neighboring cells[48].  Recent work has shown that lactic 
acid secretion is important for the invasive properties of malignant glioma [49].  
Moreover, tumor cells have been found to produce more oxygen radicals and hydrogen 
peroxide, which can also be released to do damage on surrounding cells [50, 51].  Finally, 
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increased hydrogen peroxide and accumulation of glycolytic intermediates due to 
upregulation of glycolysis can activate HIF-1 signaling.  HIF-1 can activate a variety of 
genes, among which are matrix-metalloprotease-2 and vimentin, which are important in 
the metastatic process [52]. HIF-1 also inhibits the cell-adhesion cadherin proteins, which 
would allow cells to detach and move freely [53].   
The mevalonate pathway: crossroads of metabolism and motility 
The mevalonate pathway, also known as the cholesterol synthesis or isoprenoid 
biosynthesis pathway, is necessary for the production of a wide variety of metabolites 
including cholesterol and hormone precursors[54].  In addition, this pathway produces 
prenyl groups, which are required for the membrane localization of small GTPase 
proteins.  The prenyl groups, farnesyl pyrophosphate and geranylgeranyl pyrophosphate 
are covalently added to specific targeting sequences on proteins, such as the CaaX box on 
RhoC, where C is a cysteine residue, a is an aliphatic amino acid, and X is a specific 
terminal amino acid which varies among the different enzymes[55].  The prenyl groups 
on small GTPases allow them to embed themselves into the cell membrane, which enable 
them to direct cell motility [56].  In this way, the mevalonate pathway lies on the 
intersection of cell motility and metabolism.  
Statin drugs, such as atorvastatin (Lipitor) have been used for many years to treat 
hypercholesterolemia.  Statins target HMG (3-hydroxy-3-methylglutaryl)-CoA reductase, 
the first enzyme in the mevalonate pathway[55].  This pathway is also targeted by 
bisphosphonate drugs, which are used primarily to increase bone mass in osteoporosis 
patients[55].  In addition, both GGTIs (geranylgeranyl transferase inhibitors) and FTIs 
(farnesyl transferase inhibitors) target this pathway.  New evidence suggests that 
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targeting the mevalonate pathway may be an effective way to treat cancer.  Nitrogen-
containing bisphosphonate drug zoledronic acid is currently used in the clinic to decrease 
incidence of skeletal related events and bone loss in breast cancer patients [57-59]. 
Additionally, the mevalonate pathway may play a role in breast cancer incidence.  Some 
studies suggest that colorectal cancer risk is reduced in patients on long-term statin 
therapy[60].  Also, retrospective studies of women taking zoledronic acid have reduced 
breast cancer risk[61]. 
MAPK p38 gamma introduction 
Recent work has shown that RhoC expression level is regulated by p38γ, an 
important member of the MAPK (mitogen-activated protein kinase) signaling cascade 
[62].  The MAPK cascade is an important regulator of cell proliferation, migration and 
motility [63].  The p38 protein has four splice-isoforms, α, β, γ, and δ.  Isoforms α and β 
are homologous as are isoforms γ and δ, however it appears that all isoforms have a 
unique function.  In the literature, primarily isoforms α and β are studied, and known p38 
chemical inhibitors are only active against a conserved ATP binding site present in α and 
β isoforms that γ and δ isoforms lack[64].  Knockdown of p38γ abrogated cell motility 
and increased the proliferative rate in these cells.[62] 
The MAPK pathway is frequently dysregulated in cancer[65].  To initiate 
signaling of the MAPK pathway, ligands such as growth factors bind to membrane bound 
tyrosine kinase receptors (RTKs) which dimerize and transphosphorylate their 
cytoplasmic tails. These phosphorylated tails then recruit other proteins to dock and form 
signaling complexes.  In cancer, the RTKs are often altered by mutations making them 
constitutively active, where they do not require ligand or dimerization to be activated, or 
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RTK genes are amplified, resulting in a greater overall signal due to increased 
dimerization partners available[63].  In addition, cancer cells may increase both autocrine 
and paracrine signaling, which leads to increase MAPK activation[63]. 
The MAPK pathway and the AKT/PI3K pathway interact to regulate cell growth 
and proliferation with the mammalian target of rapamycin (mTOR) [66].  In addition, 
these pathways work together to modulate HIF-1α, which is critical for regulating the 
response to hypoxia[15].  Because mTOR plays such a significant role in regulating cell 
metabolism, fully understanding the interactions and cross-talk between the MAPK and 
AKT/PI3K pathways and mTOR will be vital to teasing out the regulation of metabolism 
in cancer cells.  
The remaining chapters of this work discuss the mevalonate pathway and its 
potential as a therapeutic target, TCA cycle metabolism and an alternative metabolic 
pathway found in a breast cancer cell line, and studies examining the altered metabolism 
found in p38γ knockdown cells.  A brief synopsis of each chapter follows. 
 
 
Chapter II: Zoledronic acid treatment prevents phosphorylation of CUB-domain 
containing protein 1 and leads to decreased motility and invasion in breast cancer 
In this chapter, the effect of three different inhibitors of the mevalonate pathway –
atorvastatin, zoledronic acid, and GGTI-298–is examined on metastatic properties of 
breast cancer cells.  In addition, an alternative mechanism independent of mevalonate 
pathway inhibition is proposed for zoledronic acid.  In this mechanism, zoledronic 
prevents the activation of CUB-domain containing protein 1 (CDCP1), which is an 
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important regulator of invasion and metastasis.  CDCP1 must be both cleaved and 
phosphorylated on its tyrosine residue to recruit its downstream signaling partners.  
Zoledronic acid prevents phosphorylation of CDCP1, thus preventing signaling 
downstream of CDCP1. 
 
Chapter III: Alternative pathway for acetyl CoA metabolism prevents 
inflammatory breast cancer cell line SUM149 from undergoing oxidative 
phosphorylation 
In this chapter, the metabolic properties of inflammatory breast cancer cells are 
examined using the cell line model SUM 149.  An alternative pathway is uncovered in 
which acetyl-CoA is used for the synthesis of N-acetyl aspartate instead of citrate 
synthesis.  The redirection of acetyl-CoA prevents accumulation of other substrates in the 
TCA cycle required for oxidative phosphorylation.  As a result, SUM149 cells do not 
undergo oxidative phosphorylation. 
 
Chapter IV: Unbiased metabolomic screening reveals key metabolic pathways 
responsible for energy switch from proliferation to motility in breast cancer cells 
In this chapter, unbiased metabolomic screening is used to uncover a possible 
behavioral switch in cancer cells that results in a change of energy use from a 
proliferative program to a motility program.  In this paper, MDA-MB-231 cells are used 
as a model with p38γ MAPK stably knocked down with shRNA.  Several metabolic 
pathways are discovered to be differentially regulated by p38 γ knockdown.  
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Perturbations of these pathways show which is the most important in the metabolic 
switch between proliferation and motility.   
 
Discussion and Future Work 
Dissecting the metabolic alterations that lead to metastasis will provide a new 
prospective for understanding the process by which cells gain the ability to metastasize.  
Understanding metabolic alterations that occur in cancer progression can lead to the 
identifications of targets for chemotherapy, as well as new treatments to prevent breast 
cancer metastasis.   Because cancer often relies on certain pathways and is unable to 
redirect its metabolism as easily as a normal cell, metabolic therapies may be much more 





Figure I.1: Overview of Glucose Metabolism 
Glucose is broken down into pyruvate via glycolysis and either made into lactate or acetyl-CoA for entry 
into the TCA cycle where substrates for a variety of biological processes are generated including succinate 
and NADH for oxidative phosphorylation. 
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Figure I.2: Glycolysis  
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Figure I.3: The TCA Cycle 
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Figure I.4: Gluconeogenesis 
Enzymes different from those used in glycolysis are shown in red with their reaction products and 
requirements.  
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Zoledronic acid treatment prevents phosphorylation of CUB-domain containing 
protein 1 and leads to decreased motility and invasion in breast cancer 
 
Abstract 
Zoledronic acid (ZA) has been shown to retard the spread of breast cancer to bone 
and viscera and is used in the clinic to ameliorate the effects of bone metastases and for 
the treatment of osteoporosis.  As ZA is a known inhibitor of the mevalonate pathway 
enzyme farnesyl pyrophosphate synthase, the mechanism behind ZA’s effect on 
metastasis was studied in comparison with two other mevalonate pathway inhibitors: 
atorvastatin (AT), a known HMG-CoA inhibitor, and GGTI-298, a geranylgeranyl 
transferase inhibitor. Treatment with AT and GGTI-298, but not ZA, decreases the 
membrane localization of motility regulators RhoC, RhoA, Rac and Cdc42, which is a 
robust surrogate for their activation.  Despite the fact that ZA did not induce an effect on 
small GTPases localization, ZA decreased cell motility and invasion in these cells, 
suggesting an alternate mechanism of action for ZA. For the first time, a novel effect of 
ZA on the modulation of CUB-domain containing protein 1 (CDCP1) activity, an 
important regulator of cancer cell invasion and motility, is identified.  ZA altered both the 




The acquisition of metastatic capabilities by cells often accompanies the 
development of  mesenchymal characteristics, such as a reduction in cell-cell adhesion, 
an increase in protease secretion, and an elongated morphologic phenotype[67-70]. This 
multimodal transformation is termed the epithelial-to-mesenchymal transition (EMT) and 
is one of the first steps in the metastatic cascade [67, 69]. An important component of 
metastasis is cellular motility, which is regulated in many normal mesenchymal-like cells 
by small GTPase proteins, including Rac, Cdc42, RhoA and RhoC; all of which are 
prenylated and thus their function is intertwined with the mevalonate pathway, as they 
play major roles in aberrant motion and focal adhesion dynamics in various cancers[71, 
72].  These proteins control the polymerization and depolymerization of actin filaments 
including lamellipodia, filopodia, and stress fibers in the protrusion-retraction cycle of 
cell motility [31, 73, 74].  Lamellipodia, controlled by active Rac, are flat, wide 
protrusive filaments.  Filopodia, controlled by active Cdc42, are small extensions. Lastly, 
stress fibers, controlled by RhoA and RhoC, pull the rear of the cell forward [70, 73, 74]. 
The fact that these GTPase proteins are up-regulated in aggressively metastatic breast 
cancers has generated interest in studying inhibitors of their activation or function as 
potential anti-cancer drugs that specifically inhibit metastases.[31, 75] 
Inflammatory breast cancer (IBC) is used in this study because of the prominent 
role that Rho GTPases play in this metastatic and lethal form of breast cancer[76]. One 
powerful molecular hallmark of IBC is overexpression of the small GTPase RhoC, which 
is present in over 90% of IBC tumor samples and causes an IBC-like phenotype when 
expressed at high levels in non-cancerous cells [72, 77-79]. While primary IBC tumors 
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have the potential to metastasize quickly, they do not undergo complete classical EMT 
and instead retain cell-cell adhesion markers such as E-cadherin and β-catenin, and 
invade through surrounding tissue in cell groups or sprouts, termed emboli [68, 80]. 
The relative abundance and activation of Rho GTPase proteins in breast cancers 
in general, and RhoC in IBCs in particular, motivated the exploration of the signaling 
pathways responsible for their activation as potential therapeutic targets. The mevalonate 
pathway synthesizes prenyl groups, namely both farnesyl and geranylgeranyl groups, and 
attaches these groups to many proteins including the small GTPase proteins Rac, Cdc42, 
RhoA and RhoC. Attachment of prenyl groups targets these proteins to the lipid 
membrane for activation.[75, 81-83]  Prenylation is considered key to the function of 
GTPases in motility and invasion. 
In order to address the role of the mevalonate pathway in modulating metastases, 
inhibitors of three different enzymes in the pathway were compared: (1) the HMG-CoA 
(3-hydroxy-3-methylglutaryl CoA reductase) inhibitor atorvastatin (AT), (2) 
geranylgeranyl transferase inhibitor GGTI-298, and (3) the farnesyl pyrophosphate 
synthase inhibitor[84, 85] zoledronic acid (ZA) (Figure II.1A).   Each of these drugs 
either shows anti-cancer activity in pre-clinical testing (GGTI-298) or is already in 
widespread use for neoplastic or non-neoplastic conditions (AT and ZA).   
Statins, including AT, are approved to treat hypercholesterolemia, and have 
recently been shown to hinder tumor cell adhesion, migration, proliferation, and invasion 
in some cancer cell lines [86-90]. Geranylgeranyl transferase inhibitors (GGTIs) are 
known to inhibit in vitro invasion, proliferation and cancer cell migration, and induce 
RhoA translocation from the cytoplasm to the membrane in breast and colorectal cancer 
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cells [56, 90, 91]. Nitrogen-containing bisphosphonates, the most potent of which is 
zoledronic acid, are effective at treating osteoporosis and skeletal-related disease [57, 59, 
92].  Nitrogen-containing bisphosphonates also inhibit cancer cell invasion and 
migration, induce apoptosis and cell cycle arrest, and prevent prenylation of RhoA [93, 
94]; however detailed work uncovering the exact mechanism for its anti-cancer potential 
has not been fully elucidated. 
In this chapter, the effects of three mevalonate pathway inhibitors (Figure II.1A) 
— ZA, AT, and GGTI-298 — on the metastatic properties of an aggressive, triple-
negative breast cancer cell line (MDA-MB-231) and an IBC derived cell line (SUM149) 
are studied.  The results reveal that GGTI-298 and AT inhibit every major in vitro 
cellular property believed to be characteristic of metastatically-enabled cells (MDA-MB-
231 and SUM149), but not in non-transformed epithelial cells (MCF10A cells), 
implicating the mevalonate pathway as a crucial pathway for metastasis that is 
differentially active in these cancer cells.  Despite the fact that ZA also inhibits in vitro 
live cell motility and invasion, it does not affect prenylation of RhoC, RhoA, Cdc42 or 
Rac, suggesting that it acts via a divergent mechanism.  An alternative mechanism of 
action for ZA on cell motility and invasion is reported.  In this mechanism, the activation 
of CDCP1, an important regulator of motility and metastasis that is often dysregulated in 





Mevalonate pathway inhibitors atorvastatin and GGTI-298 significantly alter the 
morphology of breast cancer cells. 
The effect of the three mevalonate pathway inhibitors on cell morphology was 
examined with immunofluorescence (Figure II.1B).  Both AT and GGTI-298 altered the 
round cell shape to a more elongated or fusiform shape.  This change was quantified 
(Figure II.1C) by measuring the aspect ratio, as described in the methods.  ZA did not 
affect the cell shape of any of the cell lines, while AT had a significant effect on the 
shape of all three cell lines. GGTI only affected the shape of the two breast cancer cell 
lines.  The changes in cell shape suggest that the mevalonate pathway inhibitors may also 
alter the ability of these cells to move [96]. This finding led us to examine motility in 
these cells. 
Mevalonate pathway inhibitors decrease both individual and collective cell motility 
In cancer progression, cancer cells often use either individual or collective cell 
movement to invade into their surrounding environment.  To determine the effect of 
mevalonate pathway inhibition on cell motility, both individual and collective motility 
were examined.  Single cell motility was studied with a bead motility assay and live cell 
microscopy (Figure II.2A, II.2B, II.7).  These experiments showed that the mevalonate 
pathway inhibition decreased the motility of the cancer cell lines, but not the normal 
breast cell line MCF-10A.   In addition, ZA had no effect on the individual cell motility 
of SUM149 inflammatory breast cancer cells.   
To examine collective cell motility, quantitative wound-healing assays were 
performed (Figure II.2C, D).  The mevalonate pathway inhibitors GGTI-298 and AT 
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were also effective in decreasing collective cell motility.  Interestingly, ZA had no effect 
on the collective cell motility of MDA-MB-231 cells, but affected collective cell motility 
in SUM149 cells, which is a very important characteristic in IBC, because it is reported 
that IBC uses primarily collective cell motility to invade[68].  These results suggest that 
ZA may affect motility through a different mechanism than GGTI-298 and AT in these 
cell lines. 
Mevalonate pathway inhibitors alter cell-cell adhesion in aggressive breast cancers 
Collective cell migration depends on both the actin cytoskeleton and cell-cell 
adhesion. Due to the striking differences in collective cancer cell migration observed 
upon drug treatment, the expression and localization of cell-cell adhesion markers E-
cadherin and β-catenin were analyzed (Figure II.3). E-cadherin expression was 
unchanged in SUM149 cells upon treatment with all 3 drugs, but its localization was 
more dispersed throughout the cytoplasm instead of mainly existing in the plasma 
membrane (Figure II.3A). The expression of β-catenin in SUM149 cells decreased upon 
drug treatment (Figure II.3B, C). As reported in the literature, MDA-MB-231 does not 
express E-cadherin with or without drug treatment (Figure II.3C). A weak β-catenin 
signal in MDA-MB-231 cells was observed, which increased upon treatment with AT 
and GGTI-298 (Figure II.3C), but not ZA.  
Inhibition of the mevalonate pathway reduces the invasion of breast cancer cells  
Another important component of the metastatic process is the invasion of tumor 
cells into the surrounding tissue.  Invasion was measured and quantified using a Boyden 
chamber assay (Figure II.4A, B).  The mevalonate pathway inhibitors effectively reduced 
the invasion of cells through the membrane, except for ZA in SUM149 cells.  MCF-10A 
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cells were not used in this experiment because they, like other non-tumorigenic cells, do 
not possess the ability to invade. 
Mevalonate pathway inhibitors alter the cellular localization of small GTPases.   
Because treatment of cancer cells with mevalonate inhibitors led to a reduction of 
motility and invasion, it was hypothesized that this was caused by an inability of the 
small GTPase motility proteins to properly localize within cells.  This change in 
localization could be due to a reduced addition of prenyl groups to these proteins via the 
effects of GGTI-298 or a reduced production of these groups due to AT or ZA action 
(Figure II.1A). To test the hypothesis, the expression levels of small GTPase proteins in 
both membrane and cytoplasmic cell fractions were measured (Figure II.5).  Both AT and 
GGTI-298 prevented the localization of GTPases RhoC, RhoA, Rac, and Cdc42 to the 
membrane of cancer cells. This is shown by the reduction of these proteins in the 
membrane fraction and accumulation in the cytoplasm. ZA was unable to prevent 
membrane localization, however, suggesting that ZA may act through a different 
mechanism from that of either AT or GGTI-298.  It has been suggested that at low 
concentrations ZA and other bisphosphonate drugs may act independently of inhibition of 
farnesyl phosphate synthase [85].  
ZA modulates protein expression and prevents phosphorylation of CDCP1 
To identify alternative targets for the mechanism of action of ZA on the motility 
and invasion of cancer cells, a gene expression microarray screen was performed on 
untreated cells and cells treated for 72 hours with ZA (Figure II.8).  Three cell lines were 
used in the screen: SUM149, MDA-MB-231, and MCF10A.    When gene expression in 
the cells treated with ZA was compared to gene expression in the untreated cells, six 
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genes were identified that had a fold change greater than 2 and were common to all 3 cell 
lines.  An additional 36 genes with a fold change greater than 2 were common to both 
cancer cell lines (Figure II.8A).  Of these 42 genes, 18 were selected for further 
validation by quantitative RT-PCR because they were either  upregulated in both of the 
cancer cell lines or downregulated in both of the cancer cells lines compared to MCF-
10A (Figure II.8B, II.6A, II.9).   The other 18 were oppositely regulated in MDA-MB-
231 and SUM 149.  Of these 18 genes chosen for quantitative RT-PCR validation, seven 
were found to have significantly different levels of mRNA expression after ZA treatment. 
Of these seven genes, CUB-domain containing protein 1 (CDCP1) was selected for 
further analysis because of its prominence in the cancer literature.   
CDCP1 is a 135 kDa protein that is cleaved in vitro to a 70 kDa protein and once 
phosphorylated plays an important role in mediating the activation of the PI3K/AKT and 
MAPK/ERK pathways, resulting in increased cell survival, motility, and adhesion [97, 
98].  At the protein level, increased expression of both cleaved and uncleaved forms of 
CDCP1 was observed in the membrane fraction of cell lysates in the cancer cells studied 
(Figure II.6B). To measure CDCP1 activation by phosphorylation on tyrosine residues, 
we conducted an immunoprecipitation experiment with anti-phospho-tyrosine and anti-
CDCP1 (Figure II.6C).  The data show that ZA treatment prevents phosphorylation of 
CDCP1 in the cancer cell lines. Taken together, these data suggest an alternate 





While mevalonate pathway inhibitors have been studied in terms of in vivo 
primary tumor growth and prevention, as well as in vitro proliferation and apoptosis, their 
effects on metastatic properties have not been comparatively delineated or studied in 
depth. In this study, cell lines with varying degrees of metastatic behavior were 
compared: MDA-MB-231, an aggressive breast cancer line and SUM149, an IBC derived 
line.  These lines were used as models of aggressive breast cancers. The effects of AT, 
GGTI-298 and ZA were not previously studied in IBC, despite the anti-metastatic 
potential of these drugs and its widespread use in patients at high risk for metastases or 
those with bone metastases. This study demonstrates that treatment with mevalonate 
pathway inhibitors induce a less aggressive phenotype in SUM149 cells across a broad 
range of in vitro assays.  Moreover, this study suggests that these drugs may act through 
unique mechanisms due to the different inhibitory properties observed in distinct assays. 
While some tumors (e.g. MDA-MB-231) metastasize in vivo primarily via single 
cells detaching from the primary tumor and targeting to lymphatic or blood vessels, a few 
tumor types (e.g. SUM149) undergo only partial EMT, and metastasize via groups or 
clusters of cells[68]. The single-cell migration results in this study are in agreement with 
previous work in which decreased migration of MDA-MB-231 cells upon treatment with 
fluvastatin or GGTI was observed [83].  The finding that all three drugs block collective 
cell migration for SUM149 cells and single-cell migration in MDA-MB-231 cells 
suggests that all of the drugs, including ZA, have therapeutic potential to prevent 
metastasis in both types of breast cancer in vivo. 
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Based on these results, the expression of two key cell-cell adhesion markers E-
cadherin and β-catenin, which are known to be involved in EMT, were analyzed. In 
MDA-MB-231 cells, β-catenin expression increases upon treatment with AT and GGTI-
298. Because MDA-MB-231 cells undergo a classical EMT, this increase in cell-cell 
adhesion likely indicates a relative loss of mesenchymal-like characteristics and it is 
presumed to result in a greater propensity for single cells to escape the primary tumor 
mass. This may explain the loss of collective cell migration observed in MDA-MB-231 
cells when treated with AT and GGTI-298, but not when treated by ZA, which itself does 
not change expression of β-catenin. 
The changes observed in single cell migration with drug treatment match those 
seen in invasion. This finding supports the notion that the force generated by actin 
protrusion and retraction in the membrane corresponds to the ability of cells to invade 
through the extracellular matrix [70]. Additionally, invasion may also be affected by 
mevalonate pathway inhibitors because of the role of Rac and Cdc42 in inducing the 
expression of secretion proteases, such as MMPs, which serve to break down the 
extracellular matrix [67]. 
Invasion is the most studied biological property with respect to the effect of 
mevalonate pathway inhibitors. Invasion is thought to be one of the in vitro properties of 
cells that most closely aligns with in vivo metastatic potential, because of its use of a 3D 
matrix that closely simulates the extracellular matrix [99]. Many groups report that AT, 
cerivastatin, simvastatin and lovastatin treatments prevent invasion of MDA-MB-231 
cells, melanoma cells, H-Ras MCF10A cells, and COLO 320DM colon cancer cells 
respectively, through a Matrigel transwell chamber [81, 89, 90]. In addition, Kusama et 
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al. report that use of GGTI-298 also inhibits the invasion of COLO 320DM colon cancer 
cells [90].  Our results are in agreement with the literature and indicate that statins may 
have promising anti-metastatic potential in vivo.  
Several studies have reported translocation of RhoA and RhoC from the 
membrane to the cytoplasm upon treatment with statins and GGTI-298 in melanoma, 
colon and breast cancer cells [81, 83, 86, 90]. The data presented here strongly support 
these results in additional cell lines and has led to the recognition that Rac and Cdc42 
undergo the same translocation upon treatment with these inhibitors.  ZA, despite having 
been ascribed a similar mechanism of action in the literature, is much less effective than 
statins or GGTIs at preventing Rho GTPase membrane localization. 
The decrease in Rac activation can explain the significant loss of lamellipodia in 
AT and GGTI-298 treated MDA-MB-231 and SUM149 cells. The long, thin projections 
remaining after drug treatment could be simply elongated filopodia (controlled by active 
Cdc42), or stress fibers (controlled by RhoA and RhoC). The inability of ZA to prevent 
activation of the small GTPase proteins is a plausible explanation for its minimal effects 
on cytoskeletal architecture, which is a surprising result of our study. 
The inability of ZA to prevent small GTPase localization to the membrane in 
aggressive breast cancer cells led to an investigation of the possibility that ZA may be 
targeting an alternate pathway.  Utilizing gene expression microarrays, several plausible 
alternate targets were identified and validated by quantitative RT-PCR.  It was found that 
ZA alters mRNA and protein expression levels of CDCP1 in aggressive breast cancer 
cells.   In addition, it was found that ZA prevents the phosphorylation of CDCP1, which 
is required for this protein’s activation.  The possibility that inhibition of activation of 
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CDCP1 is a major effector of the action of ZA in aggressive breast cancers is depicted by 
a mechanistic model, shown in Figure II.6D.  
CDCP1 expression has been implicated in several cancers as a potential anti-
tumor target.  CDCP1 protein is activated by both a cleavage event and phosphorylation.  
CDCP1 cleavage has been shown to activate the pro-survival, anti-apoptotic AKT 
pathway [100], while phosphorylation of CDCP1 by src-family kinases (SFKs) leads to 
the recruitment of PKC-δ, and increased cell motility and resistance to anoikis [100].  
Because ZA treatment increased both the cleaved and uncleaved forms of CDCP1 and 
CDCP1 cleavage has been shown to activate the pro-survival, anti-apoptotic AKT 
pathway, we postulate that ZA’s inhibition of CDCP1 activation via phosphorylation 
leads to increased CDCP1 expression at the mRNA and protein level in an attempt to 
overcome this inhibition. 
Along with identifying CDCP1 as a potential target of the anti-tumor action of 
ZA, the gene expression microarray analysis also identified 23 genes that are regulated in 
opposite directions by ZA in the MDA-MB-231 and SUM149 cell lines.  This may help 
to explain the differential ability of ZA to modulate the metastatic potential of MDA-
MB-231 and SUM149 cells.  We propose that these genes may be worthy of further 
investigations in this regard.   
Recently, retrospective studies have shown that women taking ZA to prevent 
osteoporosis have reduced incidence of breast cancer [59, 61].  The mechanism 
explaining how ZA might act to prevent breast cancer occurrence is currently unknown.  
The new model we propose for the mechanism of action of ZA may also help to explain 
this drug’s role as a breast cancer prevention agent.  In the future, it will be informative to 
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test mice that are genetically modified to develop breast cancer with ZA to evaluate for 
delays of onset or reduction in breast cancer risk.   
Based on these data, we conclude that the mevalonate pathway remains an 
attractive candidate pathway for drugs targeting metastasis. Statins and bisphosphonates 
are routinely used for treatment of other diseases with minimal toxicity. First-generation 
GGTIs, however, have shown unacceptable toxicities in mice and human patients. Lobell 
et al. report that GGTIs may cause edema and decreased blood pressure at doses high 
enough to prevent Ki-Ras prenylation [101]. However, Sun et al. report no negative side 
effects for GGTI treatment at lower doses [102].  In our studies, MCF-10A, used as a 
normal-like control cell line, shows little evidence of direct toxicity upon treatment with 
GGTI, with the exception of lower single cell velocity with GGTI-298. However, in vivo 
toxicity testing at corresponding doses in mice has not been conducted.  Therefore, both 
AT and ZA appear to be excellent drugs for future detailed murine studies to delineate 
their anti-metastatic properties in vivo for further clinical development as anti-metastatic 
agents.  
Methods 
Cell culture and drug treatment 
MCF10A cells were cultured in 1:1 Ham’s F-12 and Dulbecco’s modified Eagle’s 
medium (DMEM) with 2 mM L-glutamine supplemented with 5% horse serum, 
extracellular growth factor, cholera toxin, insulin, hydrocortisone, gentamycin, 
fungizone, and penicillin/streptomycin at 37ºC under 5% CO2. MDA-MB-231 cells were 
cultured in RPMI 1640 supplemented with 10% fetal bovine serum, gentamycin, 
fungizone and penicillin/streptomycin at 37ºC under 5% CO2. SUM149 cells were 
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cultured in Ham’s F-12 with L-glutamine supplemented with 5% fetal bovine serum, 
insulin, hydrocortisone, gentamycin, fungizone and penicillin/streptomycin under 10% 
CO2. 
For drug treatment, all cells were grown to 30-50% confluence, serum starved for 
16-20 hours, then treated with 10μM AT (dissolved in methanol) or 10μM GGTI-298 
(dissolved in DMSO) for 48 hours total, or with 10μM ZA(dissolved in PBS) for 72 
hours total in serum-containing medium. Medium containing ZA was replaced after 48 
hours. Drug concentration and treatment times were determined based on what has been 
previously reported in literature [83, 102-105] and results from cell proliferation assays 
(MTT assays, data not shown). The concentrations used were effective at inhibiting 
growth of MDA-MB-231 and SUM149, but not MCF10A cells.  
Phospho-CDCP1 Immunoprecipitation/Western blotting 
Protein was extracted from 70% confluent cells with radioimmunoprecipitation 
assay buffer with Complete Mini protease inhibitor cocktail (Roche) added. Total protein 
extracts were incubated with primary antibody (anti-CDCP1 or anti-phospho-tyrosine) 
overnight at 4°C. The following morning protein–antibody complexes were captured by 
incubation with protein A/G beads (eBioscience). Immunoprecipitates were run on an 
SDS-PAGE gel, transferred to a polyvinylidene fluoride (PVDF) membrane, and probed 
with the appropriate reciprocal antibody (anti-CDCP1 or anti-phospho-tyrosine). All 
immunoprecipitation and Western blot data represent at least 3 independent experiments. 
Protein extraction and Western blot 
Cells were washed with cold phosphate-buffered saline (PBS) and lysed in a 
radioimmunoprecipitation assay buffer plus protein inhibitor cocktail. Cells were sheared 
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with a 23 gauge syringe and protein was collected after centrifugation. 30-60µg of 
protein was electrophoresed onto a SDS-PAGE gel (12.5%). The protein was transferred 
to a PVDF membrane using a semidry apparatus (BioRad). The membrane was blocked 
using 5% milk in TBST and incubated in 5% bovine serum albumin (BSA) in TBST with 
Cell Signaling antibodies anti-RhoC (1:1000 dilution),  anti-Rac (1:2500), anti-Cdc42 
(1:500) or Santa Cruz antibodies anti-RhoA (1:500), anti-E-cadherin (1:500), and anti-β-
catenin (1:500) or BD antibody anti-β1 integrin (1:500). The membrane was incubated in 
5% milk in TBST with Santa Cruz antibody anti-actin (1:1000) or in 3% milk in PBS 
with Upstate antibody anti-RhoGDI (1:1000). Membranes were incubated with anti-
rabbit, anti-rat or anti-mouse secondary antibodies conjugated to horseradish peroxidase 
(HRP) at concentrations of 1:5000 in 5% milk in TBST. Protein bands were detected by 
autoradiography. All Western blot data represent at least 3 independent experiments.  
Subcellular fractionation 
Subcellular fractionation into membrane (M) and cytosol (C) fractions was 
performed as described previously [106].   Briefly, cells were washed, treated with lysis 
buffer and scraped from cell plates.  Lysates were homogenized using a Teflon pestle and 
a Dounce Homogenizer.  Homogenized cells were centrifuged to pellet nuclei, and then 
the supernatant was spun to pellet the membrane.  Cytosol remained in the supernatant.  
A Bradford assay was conducted to measure total protein of each fraction. 
Immunofluorescent staining 
Cells were plated in 4-well collagen I-coated glass slides prior to drug treatment. 
After drug treatment, cells were fixed with 4% paraformaldehyde in PBS and 
permeabilized in 0.5% TritonX-100 at 4°C. Cells were blocked with 10% goat serum in 
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PBS and incubated with primary antibodies (the same antibodies and concentrations as 
for Western blots) and anti-rat or anti-mouse fluorescently tagged secondary antibodies 
(at 1:1000 dilutions) in goat serum. Cells stained only with Rhodamine/AF568-Phalloidin 
(actin) were fixed, permeabilized and incubated with a 1:50 dilution for 20 minutes.  
Coverslip was attached using Prolong Gold with DAPI.  
Aspect Ratio Measurement 
The aspect ratio (longest length divided by perpendicular width) of cells was 
measured using Image J software.  Between 50 and 120 cells were measured for each 
condition. 
3D cell culture 
Cells were cultured on top of BD Collagen Matrigel in 8-well glass slides in 
normal medium supplemented with 5% Matrigel according to the protocol developed by 
Lee et al. 2007[107]. MCF10A cells were plated at a density of 500 cells per well, and 
were grown for a total of 7-8 days (3-4 days prior to drug treatment). MDA-MB-231 cells 
were plated at a density of 1500 cells per well for a total of 6-7 days (2-3 days prior to 
drug treatment). SUM149 cells were plated at a density of 1500 cells per well for a total 
of 8-9 days (4-5 days prior to drug treatment). Cell medium was replaced every two days.  
Bead motility assay 
The Cell Motility Assay (Thermo Scientific Cellomics) was used to measure 
single cell motility. Blue fluorescent beads were washed using 1X wash buffer 
(Dulbecco’s PBS) at pH 7.2. Beads were plated into a collagen-coated 96-well plate and 
incubated at 37°C for 1 hour. The beads in the wells were washed 5 times with 1X Wash 
buffer. Pre-treated MCF10A, MDA-MB-231 and SUM149 cells were plated in the bead-
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coated wells at a density of 400-600 cells/well and incubated for 16-24 hours (MCF10A 
and MDA-MB-231) or 40-48 hours (SUM149). Longer incubation times for SUM149 
cells were required because they migrate slower than MDA-MB-231 cells in vitro, 
despite their motile and aggressive behavior in vivo. Images were taken of the center of 
each well (20X) using a Leica DMIRB microscope. 2 separate experiments with 5 
replicates each were performed.  
Live cell imaging 
Cells were plated in 2 or 8 well Collagen I-coated glass-bottomed slides. Cells 
were treated in the slides and imaged 24 hours prior to the end of the treatment. Cells 
were imaged on an Olympus Deltavision-RT microscope once every 3 minutes for 12-18 
hours total. For each experiment, 10 videos were taken per sample. At least 2 
experiments were done per cell line per drug treatment to verify that cell behavior was 
the same, but only one experiment (75 cells) was analyzed for cellular velocity. Cellular 
velocity was analyzed using the ImageJ MTrackJ plugin. 
Invasion assay 
1-5×105 SUM149 or MDA-MB-231 cells were plated in BD BioCoat Matrigel 
Invasion Chambers in serum-free medium and chemoattractant (growth medium with 
serum) was added to the well beneath. Cells were incubated in the chambers for 24 hours 
(MDA-MB-231) or 48 hours (SUM149). Cells attached to the bottom of the inserts were 
fixed and stained with 1% crystal violet in methanol. Stained inserts were imaged using a 
Leica MXFL III stereo microscope. The stain was dissolved in 10% acetic acid and 
absorbance measured at 590nm.  Before being plated into the invasion wells, cells were 
pre-treated such that the total treatment time (including the time the cells spent in the 
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invasion wells) was 48 hours for AT and GGTI-298 and 72 hours for ZA. A control assay 
was performed to verify that passaging the cells post-treatment did not affect their ability 
to adhere again to tissue culture plates upon continued treatment (data not shown).  
Scratch assay 
Cells were plated into 6-well plates at the following densities: 0.6×105 MCF10A 
cells per well, 1.5×105 MDA-MB-231 cells per well, and 2.5×105 SUM149 cells per 
well. Confluent plates were scratched with a sterile pipette tip 3 days after cells were 
plated for all three cell lines.  Images were taken immediately after the scratch and the 
plate was marked in order to locate the same spot again either 24 hours later (for 
MCF10A and MDA-MB-231 cells) or 48 hours later (for SUM149 cells). Though in this 
experiment the SUM149 cells were incubated for a longer period of total time with the 
drug, their cell plates were also scratched one day earlier and the result was identical. 
Wound closure was quantified using ImageJ software.  
Microarray Methods 
RNA was isolated from MCF10A, MD-MBA-231, and SUM-149 cell lines grown 
with or without ZA treatment using Trizol according to the instructions.  RNA was 
cleaned using the RNAeasy MinElute Cleanup Kit (Qiagen) according to instructions, 
and submitted to the University of Michigan Microarray Core.  One experiment was done 
in duplicate.  Expression values for each gene were calculated using the robust multi-
array average method [108] .  Only probesets with a 2 fold or higher change (when ZA 
treated cells were compared to untreated cells) were selected for comparison across the 




Quantitative RT-PCR methods 
RNA was isolated from cell lines grown with or without ZA treatment using 
Trizol.  The Promega Reverse Transcription System was used according to package 
instructions to make cDNA from isolated RNA.  SYBR Green Mastermix was used 
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Figure II.2: Mevalonate pathway inhibitors reduce both single-cell motility and collective cell 
motility in aggressive breast cancers 
(A) Treated and untreated MCF10A, MDA-MB-231, and SUM149 cells were plated in bead-coated wells 
and incubated according to the methods. Images were taken of the center of each well (20X). 
Representative images of 2 experiments, 5 replicates each. (B) Cell tracks were analyzed using ImageJ, and 
converted to μm2/min. At least 10 images were analyzed per sample. * indicates p<0.05 and ** indicates 
p<0.0005. Error bars, ±SD. (C) Wound healing assays according to the methods. The white lines represent 
original scratch mark prior to wound closure. A representative image of 2-3 separate experiments with 4 
replicates each is displayed. (D) The area of wound closure was quantified using ImageJ for at least 8 
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Figure II.4: Mevalonate pathway inhibitors inhibit invasion of aggressive breast cancers in vitro 
(A) Transwell invasion assays were performed according to the methods. Representative images of crystal 
violet stained inserts at 2.5X. Two identical experiments were performed in triplicate. (B) Invasion assays 
were quantified by dissolving the crystal violet in acetic acid and measuring the absorbance at 590nm. 
Quantification includes all six inserts per sample. Treated samples were normalized to the control for the 















































Figure II.5: AT and GGTI-298, but not ZA, induce RhoC, RhoA, Rac and Cdc42 translocation to the 
cytoplasm in MDA-MB-231 and SUM149 cells 
MCF10A, MDA-MB-231, and SUM149 drug treatment, protein extraction and differential centrifugation 
were performed according to the methods. (A) Displays a positive control showing the purity of the 
cytosolic and membrane fractions. β1 integrin is the control membrane-bound protein and Rho-GDI is the 
control cytosolic protein. Representative western blots for total protein (T) (n=3), membrane-bound (M) 
fraction (n=2) and cytosolic (C) fraction (n=2), indicating levels of RhoC (B), RhoA (C), Rac (all isoforms, 























































































































































































































































































Figure II.6: Treatment of cell lines with ZA increases expression of CDCP1, and prevents 
phosphorylation 
(A) Quantitative RT-PCR validation showing changes in mRNA expression of CDCP1 with ZA treatment 
in cancer cell lines.  (B) Western blot of membrane-bound CDCP1. (C) Western blot of CDCP1 after IP of 
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Figure II.7: Real-time imaging of cell movement 
MCF10A, MDA-MB-231, and SUM149 cells were imaged according to the methods. Cellular velocity was 
measured using ImageJ plugin MTrackJ. 75 cells were analyzed per sample. ** indicates p<5×10-5 Error 









































Figure II.8: Microarray to look for alternative gene targets of zoledronic acid in aggressive breast 
cancer cells 
(A) Venn Diagram of gene counts differentially expressed greater than two-fold with zoledronic acid 
treatment. (B) Heatmap of 6 genes that were differentially expressed in all cell lines tested after zoledronic 
acid treatment as well as 36 genes that were differentially expressed in MDA-MB-231 and SUM149 (but 





Figure II.9: Validation of hits from microarray data using Quantitative RT-PCR 
Quantitative RT-PCR was used to validate selected microarray data.  Only mRNA that showed significant 
expression level changes with ZA treatment are shown.  Top panel shows complete data, bottom panel 
shows truncated data to show detail.  This experiment was done three independent times in triplicate.  
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Alternative pathway for acetyl CoA metabolism prevents inflammatory breast 
cancer cell line SUM149 from undergoing oxidative phosphorylation 
 
Abstract 
In the last 20 years, great advances have been made in the field of cancer 
metabolism.  For example, alterations leading to changes in glycolysis due to differences 
in isoform expression of pyruvate kinase and regulation changes in phosphofructokinase 
have been identified [10, 11, 15].  Additionally, mutations in tricarboxylic acid (TCA) 
enzymes including isocitrate dehydrogenase have been discovered [18, 19].  However, 
the metabolic changes that occur in the rare and very aggressive inflammatory breast 
cancer (IBC) have not been previously studied.  To characterize metabolic homeostasis 
that occurs in IBC, our lab used the cell line SUM149, derived from an IBC tumor, as 
well an aggressive triple negative breast cancer cell line, MDA-MB-231; normal-like 
breast epithelial cell line MCF-10A was used as a control.  We performed bioenergetic 
profiling and mass-spectrometry-based metabolomics to assess metabolic differences 
between these cell lines.  We demonstrate that SUM149 cells lack the ability to undergo 
oxidative phosphorylation.  Additionally, these cells produce high levels of the 
metabolite N-acetyl-aspartate (NAA), a compound previously uncharacterized in IBC 
cells.  Correspondingly, SUM 149 cells show near 20-fold upregulation of N-acetyl-
aspartate transferase 8-l9ke (NAT8L) mRNA.  This metabolic pathway may divert 
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pyruvate-derived acetyl CoA from the TCA cycle to formation of NAA, potentially 
contributing to the observed defect in oxidative metabolism. 
Introduction 
Inflammatory breast cancer is the most deadly form of breast cancer.  It is very 
aggressive and consists mainly of large clusters that behave as tumor emboli, plugging 
lymphatic vessels in the skin overlying the breast and metastasizing sometimes even 
before the primary lesion is detected [109].  Because of the lack of targeted therapy for 
this disease, studies of the metabolic phenotype of this type of cancer were pursued in 
order to uncover special metabolic vulnerabilities that may be exploitable for therapeutic 
purposes. It has been shown that metabolic alterations that occur in cells play an 
important role in the development and aggressiveness of cancer [110, 111]; however the 
metabolic characteristics of inflammatory breast cancer have never been elucidated in 
detail.   
 By probing various metabolic pathways via bioenergetic profiling, mitochondrial 
enzyme activity assays and mass-spectrometry based metabolomics, we report here that 
SUM149 cells lack the ability to undergo oxidative phosphorylation due to an unknown 
defect which prevents the formation of TCA cycle intermediates for use in oxidative 
phosphorylation.  Specifically, SUM149 cells do not direct acetyl-CoA made from 
pyruvate via glycolysis into the TCA cycle, but instead use it to acetylate aspartate 
generated from glutamine entering the TCA cycle via glutaminolysis.  N-acetyl aspartate, 
a metabolite of unknown function outside the central nervous system, builds up to very 
high levels in the cell.  As a result, very low amounts of early TCA cycle intermediates, 
like citrate and isocitrate, are available in the mitochondrial pool.  The role that N-acetyl 
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aspartate plays in these cells, outside of serving as a de facto sink for acetyl-CoA, is yet 
to be uncovered. 
Results 
Inflammatory breast cancer cells do not use oxidative phosphorylation 
In order to determine the basal respiration and respiratory capacity of each of the cell 
lines of interest, a bioenergetic profile assay and an extracellular acidification rate assay 
were performed on live cells (Figure III.1A-C).  While MDA-MB-231 cells display a 
reduced oxidative capacity compared to the MCF-10A cells as predicted by the Warburg 
effect, SUM149 cells do not consume oxygen under the assay conditions, nor do they 
respond to any of the mitochondrial inhibitors.  SUM149 cells produce an abundance of 
lactate, as indicated by the increased extracellular acidification rate (ECAR). 
  In order to determine whether SUM149 cells can be forced to undergo oxidative 
phosphorylation under different metabolic conditions, the same experiment was 
performed under low-glucose conditions of 2.5 mM.  Even under conditions of low 
glucose, oxygen consumption rates did not change significantly (45 ± 11 pMoles/min 
under 2.5 mM glucose to 40 ± 9 pMoles/min with 11 mM glucose).  Additionally, no 
response was observed when mitochondrial inhibitors were used (Figure III.5).  As 
expected, in MCF-10A cells, low glucose increased consumption of oxygen and reliance 
of the cells upon oxidative phosphorylation for energy production.  Once more glucose 
was added to return the concentration to 11mM glucose normally used in this assay, 
lactic acid production increased to a maximum of 72 ± 12 mpH/ min, which is twice that 
of the lactic acid production rate under low glucose conditions (32 ± 5), thus accounting 
for the additional glucose present.   
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In another attempt to force SUM149 cells to undergo oxidative phosphorylation, 
galactose was given as a substrate in lieu of glucose.  Metabolism of galactose to 
pyruvate by glycolysis results in no net production of ATP, which means it can only 
serve as an energy-generating substrate through TCA cycle metabolism and oxidative 
phosphorylation.  When SUM149 cells are given galactose, they respond weakly to 
mitochondrial inhibitors (Figure III.1C).  These experiments suggest that the SUM149 
cells may lack sufficient mitochondria, that their mitochondria might be damaged, 
dysfunctional, or inefficient, or that some signaling defect is preventing SUM149 cells 
from using their mitochondria. In order to delineate any potential mitochondrial defects, 
we undertook the next series of experiments. 
SUM149 cells have sufficient numbers of mitochondria 
Several different approaches were used to determine whether SUM149 cells have 
sufficient mitochondria.  First, the protein expression of the mitochondrial marker Cox 4 
was measured. Cox 4, a subunit of complex IV within the mitochondria, was decreased at 
the protein level in SUM149 cells (Figure III.6A).   Next, the number of mitochondria per 
cell were examined using transmission electron microscopy (TEM), shown in Figure 
II.6B-D.    This experiment illustrated that SUM149 have morphologically normal 
appearing mitochondria.  Finally, quantitative-PCR was used to measure the ratio of 
mitochondrial DNA to nuclear DNA in each cell (Figure III.6E).  This experiment found 





SUM149 cells have reduced protein expression of and less efficient mitochondrial 
enzymes 
Once it was determined that SUM149 cells had sufficient mitochondria, their 
mitochondrial efficiency was investigated.  To this end, the protein expression and 
activity of several key mitochondrial enzymes were measured.  Citrate synthase, which 
catalyzes the conversion of acetyl CoA and oxaloacetate to citrate, had much lower 
expression in SUM149 and MDA-MB-231 cells (Figure III.2A).  Citrate synthase activity 
was also reduced in both cancer cell lines to 20-30 % of the activity of that in MCF-10A 
cells (Figure III.2B).  The mRNA of citrate synthase for all three cell lines was sequenced 
to look for mutations that would lower expression or activity.  No mutations were found 
in any of the cell lines (not shown). The conversion of pyruvate to acetyl CoA for entry 
into the TCA cycle is catalyzed by a multisubunit complex called the pyruvate 
dehydrogenase (PDH) complex.  This complex is made up of 3 catalytic subunits (E1, 
E2, and E3) and the E3 binding protein (E3bp).  The activity of this complex is regulated 
by 2 phosphatases (PDP1 and PDP2) which activate the complex, as well as 4 kinases 
(PDK1-4) which inhibit the complex.  The protein expression of the PDH complex was 
measured using an antibody that detects both the E2 subunit and E3 binding protein 
(E3bp).  This experiment showed that E3bp was decreased in both MDA-MB-231 and 
SUM149 cells.  Since the E3bp is important for holding the E2 and E3 catalytic subunits 
together in the complex, a lesser amount of E3bp may result in a lower overall stability of 
the complex[112].  In an activity assay, we found that the endogenous activity level of 
pyruvate dehydrogenase in SUM149 is about one-third the activity of MCF-10A cells and 
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suggests that this enzyme is mostly in its phosphorylated or “off” state, possibly due to 
regulation by the pyruvate dehydrogenase lipoamide kinases PDK1-4 (Figure III.2E).   
Pyruvate is not being used as a fuel for the TCA cycle in inflammatory breast 
cancer cells. 
Because SUM149 cells appear not to undergo oxidative phosphorylation, it was 
considered informative to investigate whether or not pyruvate is able to enter the 
mitochondria and be used as a TCA cycle substrate.  A stable isotope labeling study using 
2, 3-13C2 pyruvate was performed to track pyruvate metabolism in the cell (Figure III.3).  
This experiment showed an abundance of labeled pyruvate being converted into lactate in 
the SUM149 cells (III.3A).  Although pyruvate was also metabolized to acetyl CoA, as is 
evident by the 13C2 labeling in the acetyl-CoA pool after 15 minutes (III.3B), no label 
was detected in citrate or isocitrate in SUM149 cells (III.3C).  The fact that 13C labeling 
is detected in malate, a metabolite further downstream in the TCA cycle, suggests that 
glutamine is likely fulfilling an anapleurotic role, entering the TCA cycle as α-
ketoglutarate (III.3D).  The low levels of TCA cycle intermediates in SUM149 cells, and 
the lack of labeled pyruvate entering the pathway to make citrate and isocitrate suggested 
that acetyl-CoA may be shunted to a different pathway in these cells.  
SUM149 cells undergo gluconeogenesis 
To further describe how SUM149 cells utilize energy from  we conducted 
experiments to investigate whether they are capable of undergoing gluconeogenesis.  
Experiments tracking 2, 3-13C2 pyruvate metabolism showed a portion of labeled 2-
phosphoglycerate and 3-phosphoglycerate as well as fructose-1, 6-bisphosphate in all 
three cell lines examined (Figure III.3E, F).  The presence of 13C label in these glycolysis 
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intermediates suggests that the cells undergo gluconeogenesis.  SUM149 cells perform 
the highest fraction of gluconeogenesis compared to the other cell lines investigated, with 
about 50% of 3-phosphoglycerate and fructose-1, 6-bisphosphate being made from 
pyruvate after 15 minutes incubation with label.   
Acetyl-CoA is used to acetylate N-acetyl-aspartate in SUM149 cells 
To further investigate alternative pathways that may be active in SUM149 cells, 
we conducted an unbiased metabolomic screen using MCF-10A, MDA-MB-231, and 
SUM149 cells (Figure III.4).  Principle component analysis identified N-acetyl aspartate 
as the metabolite responsible for the greatest degree of separation between cell lines.   We 
observed a very large pool of N-acetyl aspartate in both cancer cell lines compared to a 
very small pool in MCF-10A cells (Figure III.4A).  N-acetyl aspartate is a metabolite that 
is important for brain function, but has no known function outside the nervous system 
[113, 114].  We conducted absolute quantification of the levels of N-acetyl aspartate with 
mass spectrometry (III.4B).   This quantification showed a great abundance of N-acetyl 
aspartate in SUM149 cells, roughly 11.5 times the level of this metabolite in MCF-10A 
cells.  The source of substrates for the synthesis of N-acetyl aspartate, as well as the 
enzymes responsible for its synthesis and degradation, are depicted in Figure 4C.  The 
gene N-acetyl-aspartate transferase 8-like (NAT8L) encodes an acetyltransferase enzyme 
that acetylates aspartate.  This gene is highly overexpressed in SUM149 cells at the 
mRNA level (Figure III.4D).  In addition, the aspartoacylase (ASPA) gene encodes the 
hydrolase enzyme that breaks down N-acetyl-aspartate to acetic acid and aspartate.  At 
both the mRNA level and protein level, SUM149 cells do not express this enzyme 
(Figure III.4D, E).  Additionally, we observe ASPA protein expression only in MDA-
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MB-231 cells, suggesting that while MDA-MB-231 cells are able to accumulate N-acetyl 
aspartate, they can also degrade it via ASPA (Figure III.4E).   
Discussion 
In this work, we found that SUM149 cells do not undergo oxidative 
phosphorylation.  In the literature, reduced oxidative phosphorylation as well as a 
preference for glycolysis in cancer cells has long been understood (the Warburg Effect); 
however, such a severe phenotype which is entirely unresponsive to all mitochondrial 
inhibitors has not been described.  When we examined the mitochondria of SUM149 
cells, we found that they were morphologically similar to MCF-10A and MDA-MB-231 
cells, and were present in similar numbers, suggesting that a lack of mitochondria or the 
presence of visually defective mitochondria does not explain their defect in oxidative 
phosphorylation.  When we examined the expression and activity of mitochondrial 
enzymes including citrate synthase and pyruvate dehydrogenase, we observed reduced 
protein expression and activity in both breast cancer cell lines.  This alone was not 
sufficient to explain the strong oxidative phosphorylation defect in SUM149 cells.  Stable 
isotope flux studies using 13C-labeled pyruvate revealed that SUM149 cells have very 
low levels of TCA cycle intermediates and that the labeled pyruvate is not being used to 
synthesize citrate or isocitrate.  Because labeled acetyl-CoA was detected, we theorized 
that acetyl-CoA was being used for some other purpose.  To identify other pathways that 
might be altered in SUM149 cells, unbiased metabolomic screening was performed on all 
three cell lines.  This experiment pointed to the accumulation of N-acetyl aspartate in 
SUM149 cells.  This substrate has no known function outside of the central nervous 
system.  We subsequently demonstrated that NAT8L, the enzyme that catalyzes the 
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acetylation of aspartate using acetyl-CoA as a substrate was highly overexpressed at the 
mRNA level in these cells.  Additionally, ASPA, the enzyme that deacetylates aspartate 
was silenced at the mRNA level and not expressed at the protein level.  Further work to 
determine whether NAT8L overexpression and the production of N-acetyl acetate are 
able to completely account for the defect in oxidative phosphorylation must be pursued.  
We hypothesize that knockdown of NAT8L expression or overexpression of ASPA 
protein may be able to rescue some portion of the defect in SUM149 cells.  Additionally, 
overexpression of NAT8L in MCF-10A cells may reduce their oxidative capacity. 
The outcome of these experiments will raise important questions regarding the 
role of N-acetyl aspartate in these cells and in cancer cell biology in general.  Further 
study will need to be done to fully understand the impact that this metabolite may have 
on signaling or other cellular processes.  Additional in vitro studies are needed to 
determine if overexpression of NAT8L and production of N-acetyl aspartate is a cell line 
specific effect, or if it can be generalized to other aggressive breast cancers. 
An additional intriguing finding from this work is that both normal breast and 
breast cancer cells undergo gluconeogenesis.  This result is novel, as most work suggests 
that only liver and kidney cells perform gluconeogenesis[27].  The SUM149 cell line 
undergoes gluconeogenesis at a much greater rate than the other cell lines, as evidenced 
by the fact that approximately 50 percent of its 2-phosphoglycerate and 3-
phosphoglycerate as well as fructose-1, 6-bisphosphate metabolites come from 
gluconeogenesis.  This suggests that another way of treating this aggressive breast cancer 
may be to target gluconeogenesis enzymes.  This might have the advantage of causing 
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fewer side effects, as most cells outside of the liver and kidney do not undergo 
gluconeogenesis.   
Glutamine’s role as a TCA cycle substrate has been studied extensively in cancer 
[26, 115], and the results obtained from isotope tracer experiments match what is shown 
in the literature.  Downstream TCA cycle intermediates like malate (Figure III.3D) 
showed a higher percentage of labeling in SUM149 cells, suggesting that they rely more 
on flux through glutamine than other cell lines do.  This may be due to the need for 
increasing aspartate production for N-acetyl aspartate via glutamate dehydrogenase, 
which catalyzes the reaction of oxaloacetate and glutamate to produce α-ketoglutarate for 
TCA cycle entry and aspartate.  Further work should characterize the reliance of 
SUM149 cells on glutaminolysis for TCA cycle derived metabolites and substrates for 
lipid and nucleotide synthesis. 
Methods 
Cell Culture 
MCF-10A cells were cultured in 1:1 Ham’s F-12 and Dulbecco’s modified 
Eagle’s medium (DMEM) with 2 mM L-glutamine supplemented with 5% horse serum, 
extracellular growth factor, cholera toxin, insulin, hydrocortisone, gentamycin, 
fungizone, and penicillin/streptomycin at 37ºC under 5% CO2. MDA-MB-231 cells were 
cultured in RPMI 1640 supplemented with 10% fetal bovine serum, gentamycin, 
fungizone and penicillin/streptomycin at 37ºC under 5% CO2. SUM149 cells were 
cultured in Ham’s F-12 with L-glutamine supplemented with 5% fetal bovine serum, 




Bioenergetic Profiles (BEP) and Extracellular Acidification Rate (ECAR) Measurements 
Cells were trypsinized and seeded with 100 µL fresh growth media into 24 well 
plates.  After 1 hour of incubation, an additional 150 µL of media was added.  After 
overnight incubation, media was replaced with XF Assay Medium Modified DMEM 
(Seahorse Biosciences) supplemented with 11 mM glucose and 10 mM pyruvate.  Cells 
were incubated in a 37°C non-CO2 incubator for 1 hour before being used for 
experiments.  Oligomycin, FCCP, and rotenone were used to achieve final concentrations 
of 1uM, 300 nM, and 100 nM respectively in the cell.  Galactose, when present, was at 11 
mM final concentration.  Low glucose experiments were performed using 2.5 mM 
glucose, and were later spiked with 87.5 mM glucose to bring the concentration back to 
the 11mM standard amount.  All experiments were performed using a Seahorse XF-24 
Extracellular Flux Analyzer according to standard protocols developed by the 
manufacturer (Seahorse Biosciences). 
Protein Extraction and Western Blot 
Cells were washed with cold phosphate-buffered saline (PBS) and lysed in 
radioimmunoprecipitation assay (RIPA) buffer plus Complete protein inhibitor cocktail 
(Roche).  Cells were sheared with a 23 gauge syringe and protein was collected after 
centrifugation to remove cellular debris. 30-60µg of protein was electrophoresed onto a 
SDS-PAGE gel. The protein was transferred to a nitrocellulose membrane using a 
semidry apparatus (BioRad). The membrane was blocked using 5% milk in TBST and 
incubated in either 5% milk in TBST or 5% bovine serum albumin (BSA) in TBST.  
Membranes were incubated with the appropriate secondary antibodies conjugated to 
64 
 
horseradish peroxidase (HRP) at concentrations of 1:5000 in 5% milk in TBST. Protein 
bands were detected by electrochemiluminescence. 
Transmission electron microscopy sample preparation and analysis 
Cells were plated in 10 cm dishes.  Cells were rinsed in serum free media, and 
fixed for 1 hour in 2.5% glutaraldehyde in 0.1M Sorensen’s buffer, pH 7.4. Cells were 
left at 4°C overnight in Sorensen’s buffer.  Cells were rinsed to remove glutaraldehyde 
and postfixed in 1% osmium tetroxide in Sorensen’s buffer.  Cells were then rinsed in 
water, and scraped off the plates.  Cells were pelleted and En Bloc stained for 15 minutes.  
Pellets were rinsed with water and then dehydrated in increasing ethanol solutions.  Epon 
was then infiltrated into the pellet with increasing resin concentrations.  Pellets were then 
polymerized at 60°C for 24 hours.  Pellets were cut using a microtome and images taken 
at 25,000X magnification using a CM100 Phillips TEM scope.  Images were stitched 
together using Adobe Photoshop. 
Mitochondrial Isolation 
Mitochondria were isolated as reported previously by Frezza et al [116].  Briefly, 
cells were grown to confluence in 10 cm culture plates.  Cells were washed with PBS and 
scraped off plates.  Cells were resuspended in Cell Isolation Buffer (IBc) and 
homogenized with a Teflon pestle.  Samples were then spun to remove nuclei, and then 
spun again to isolate the mitochondria.  A Bradford assay was completed on the 
mitochondrial isolates to determine concentration of total protein. 
Citrate Synthase Assay 
Isolated mitochondria were thawed and frozen in 3 cycles to disrupt 
mitochondrial membranes.  A Bradford assay was completed to correct for protein 
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content.  Reaction mixture containing 100mM Tris-HCl, 100 µM DTNB, .4% TX-100 
final concentration was added to each well in a 96 well plate.  Mitochondrial isolates 
were added at concentrations of 1-15 µg/well.  Acetyl CoA was added at a final 
concentration of 50 µM.  The plate was incubated at 37°C for 5 minutes to allow all 
endogenous oxaloacetate to be exhausted.  100 µM final concentration of oxaloacetate 
was added, and the plate was read at 412 nm for 15 minutes reading every 12 seconds. 
Sequencing of Citrate Synthase mRNA 
RNA was isolated from cell lines using Trizol according to package instructions.  The 
Promega Reverse Transcription System was used according to package instructions to 
make cDNA from isolated RNA.  PCR amplification of citrate synthase mRNA was 
conducted using the following primers: 
Forward: CTGCCGCAGCTCTCTCCCTT 
Reverse: AGGCTTCCTCACTTTCTGGTAGTCA 
The PCR product was run on an agarose gel.  The band was excised and purified using 
the Qiagen QIAquick Gel extraction kit.  The purified PCR product was then submitted 
to the University of Michigan DNA Sequencing Core for direct Sanger sequencing.  
Pyruvate Dehydrogenase Activity Assay 
Pyruvate dehydrogenase (PDH) activity was measured using a modified version 
of the method by Schwab et al [117].  Briefly, cells the cells were trypsinized, pelleted 
and rinsed, and then suspended in isolation buffer (250 mM sucrose, 1mM EGTA, 10 
mM HEPES, 5 mg/mL BSA, pH 7.5.  Half of cells were incubated with 5 mM final 
concentration of dichloroacetic acid (DCA) to fully activate the PDH complex for 15 
minutes at 37°C.  The other half were incubated without DCA.  Cells were homogenized 
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with a Teflon pestle.  Cells were then spun at 13,000 rpm in a microcentrifuge and 
frozen.  The next day cells were freeze-thawed three times and resuspended in buffer 
(.1% Triton X-100, 1 mM CaCl2, 5 mM MgCl2, 50 mM KCl, 250 mM Sucrose, 20 mM 
Tris-HCl pH 7.5).  The cells were sonicated for 20s on 50% duty cycle at 20% amplitude.  
Cells were then spun at 15,000 x g for 5 min, and the supernatant was used to measure 
protein content by a Bradford Assay.  100 µL aliquots were made for each sample 
containing 4.25 mg/mL protein.  18 µL of each sample was added to 5 wells in a 96 well 
plate. Bovine Heart Mitochondrial Lysate (abcam) was used as a positive control after 
solubilization with 1% Lauryl Maltoside final concentration and spinning at 15,000 x g.   
182 µL reaction mixture (5mM L-carnitine, 2.5 mM NAD, .2mM TPP, .1mM CoA, 5 
mM pyruvate, .1% Triton X-100, 1 mM MgCl2, 1 mg/mL BSA, .6 mM INT, 6.5 µmol 
PMS in .05M potassium phosphate buffer pH 7.5) was added to each well in a 96 well 
plate.  1.7 µL of .6M fluoropyruvate was added to 2 of the 5 wells to determine the 
amount of nonspecific activity.  The plate was read using kinetic assay settings at 500 nm 
with reads every 30 seconds for 1-3 hours depending on time to reach saturation. 
Quantitative RT-PCR methods 
RNA was isolated from cell lines using Trizol according to package instructions.  
The Promega Reverse Transcription System was used according to package instructions 
to make cDNA from isolated RNA.  SYBR Green Mastermix was used according to 
directions for Quantitative PCR.    Three experiments were done in triplicate. 
Preparation of Extracts for Targeted Metabolomics and 13C mass isotopomer analysis 
Cell extracts were prepared and analyzed according to a modified protocol from 
Lorenz et al, [118]. Cells were grown to 80% confluence on 6 cm collagen-coated tissue 
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culture plates.  Cells were then changed to unbuffered media, either XF Assay Medium 
Modified DMEM (Seahorse Biosciences) or Dulbecco’s modified Eagle’s medium base 
(D5030) supplemented with 11mM glucose, 10 mM sodium pyruvate, 2.5 mM glutamine 
and 0.015g/L phenol red.  Cells were incubated at 37°C for 1 hour in a non-CO2 
incubator.  Cells were then changed to the same media containing 2,3-13C2-pyruvate and 
incubated for 0 or 15 minutes.  Cells were then rinsed by rapid addition and removal of 3 
mL of distilled water, after which metabolism was immediately quenched by pouring 
liquid nitrogen into the plate.  Plates were stored at -80°C until extraction.  Cells were 
extracted by adding 500 µL of ice-cold 8:1:1 methanol:water:chloroform to the frozen 
cell surface and scraping with a cell scraper. The extract and residual cell debris were 
transferred to polypropylene microcentrifuge tubes and centrifuged for 5 min at 15,000 x 
g at 4°C.  The supernatant was transferred to autosampler vials and analyzed by LC-MS.  
Preparation of Extracts for Unbiased Metabolomic Screening 
7 x 10cm plates for each cell line were grown for 2-3 days to 80% confluence in 
growth media.  The plates were changed to fresh growth media one hour before 
quenching with liquid nitrogen.  Three plates from each cell line were reserved for 
protein normalization.  After the one hour incubation, the remaining four plates were 
rinsed with 4 mL deionized water and quenched with liquid nitrogen as above, then 
stored at -80°C.  Cell plate extraction was performed as described previously, except that 
the extraction solvent contained 18 µg/mL of a 13C amino acid mix (Sigma, part 426199) 
to serve as an internal standard and the volume used was increased to 1mL per plate to 
accommodate the larger plate size.  Following centrifugation, 500 µL of supernatant was 
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dried under nitrogen and reconstituted in 250 µL of water containing tert-
butyloxycarbonyl-protected amino acids to serve as injection standards.    
LC-MS Methods and Data Analysis 
For targeted metabolomics and 13C mass isotopomer analysis, samples were 
analyzed on an Agilent 1200 LC / 6520 qTOF MS system.  To obtain good retention of 
the polar, predominantly anionic metabolites of glycolysis and the TCA cycle, 
chromatographic separation was performed by mixed mode hydrophilic interaction – 
anion exchange using a Luna NH2 3µ column, 150 mm x 1 mm ID (Phenomenex, 
Torrance, CA).  Mobile phase A was acetonitrile and mobile phase B was 5 mM 
ammonium acetate in water, adjusted to pH 9.9 using ammonium hydroxide.  The 
gradient was a 15 minute linear ramp from 20 to 100%B, followed by a 5 minute hold at 
100%B and a 17-minute requilibration period at 20%B.  The column temperature was 
25°C and the flow rate was 0.07 mL/min, which was ramped to 0.09 mL/min between 20 
to 32 minutes.  The injection volume was 10 µL.  Electrospray ionization was carried out 
in negative ion mode using a source gas temperature of 350° C, a drying gas temperature 
of 10 L/min, a nebulizer pressure of 20 psig, and a capillary voltage of 3500 V.  Data 
were collected in TOF full-scan mode over m/z 50-1200 at an acquisition rate of 1 
spectra/s with reference mass correction enabled.  Data were analyzed using Masshunter 
Quantitative Analysis software.  Metabolites and their 13C isotopes were identified by 
retention time and m/z values determined from authentic standards.  Quantification was 




For unbiased metabolomics, samples were analyzed on an Agilent 1200 LC / 
6530 qTOF MS system using a Waters Acquity HSS T3 reversed-phase column, 50 mm 
x 2.1 mm ID.  For positive ion mode runs, mobile phase A was water with 0.1% (v/v) 
formic acid and mobile phase B was methanol with 0.1% formic acid.  For negative ion 
mode runs, the formic acid was replaced with 0.1% (m/v) ammonium bicarbonate.  The 
gradient was as follows: 0-0.5 min 1% B, 0.5-2 min 1-99% B, 2-6 min 99% B, 6-6.1-9 
min 1% B.  The flow rate was 0.35 mL/min and the column temperature was 40° C.  The 
injection volumes for positive and negative mode were 5 and 8 µL, respectively.    ESI-
MS conditions were the same as for targeted analysis except that the Agilent Jetstream 
source was used, the nebulizer pressure was 30 psig, and the sheath gas temperature and 
flow rate were 350° C and 11 L/min.  Data analysis was performed using a two-step 
approach using Agilent Masshunter Qualitative Analysis Software. First, known 
compounds were identified by searching the LC-MS data against an in-house metabolite 
library of approximately 600 previously-analyzed authentic standards using the find by 
formula algorithm.  Then, the molecular feature extractor algorithm was used to detect 
additional unknown features, the features were aligned between samples by mass and 
retention time, and finally these features were selected and quantitated using find by 
formula.  Principle component analysis was applied to the data to rank features in order 
of their contribution to differences in the metabolome between cell types. 
Protein Normalization of Mass Spectrometry Data 
Three additional plates were grown up in each experiment per cell line.  Cells 
were rinsed twice with cold PBS, and then treated with RIPA buffer with complete 
protease inhibitor cocktail (Roche) added at suggested concentration for 25 minutes with 
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gentle agitation at 4°C.  Protein was scraped off the plate and sheared with a 23-gauge 
syringe 3-4 times.  Protein was collected in microcentrifuge tubes and spun for 15 
minutes at 13,000 rpm at 4°C to pellet cellular debris.  A Bradford assay was performed 
to quantify the amount of protein in each sample.  This data was averaged and used to 






Figure III.1: SUM149 cells do not use oxidative phosphorylation 
Bioenergetic profiles measuring oxidative consumption rate (OCR) on left and extracellular acidification 
rate (ECAR) on right of normal and breast cancer cell lines.  A. MDA-MB-231 compared to MCF-10A B. 
SUM149 compared to MCF-10A C. SUM149 and MCF-10A using galactose as an alternative substrate 
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Figure III.2: SUM149 cells have less efficient mitochondrial enzymes 
Protein expression and enzyme activity of selected mitochondrial enzymes A. Citrate synthase protein 
expression B. Citrate synthase activity C. Pyruvate dehydrogenase protein expression level D. 

















































































Figure III.3: SUM149 cells do not use acetyl-CoA to make citrate and perform gluconeogenesis 
Stable isotope tracer experiments with 2, 3-13C2-pyruvate measuring peak intensity area under the curve of 
the following metabolites A. Lactate B. Citrate/Isocitrate C. Acetyl-CoA D. Malate E. 2-
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Figure III.4: N-Acetyl Aspartate Pool Identified in Unbiased Metabolomic Screen 
Identification and validation of N-acetyl aspartate pool in SUM149 cells. A. Peak Area of N-Acetyl-
Aspartate Pool B.  Quantification of N-Acetyl-Aspartate in stable isotope experiments C. Model showing 
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Figure III.5: Low Glucose does not induce SUM149 cells to undergo oxidative phosphorylation 
BEP (A) and ECAR (B) of SUM149 cells grown in low (2.5 mM), and then spiked with glucose to reach 
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Figure III.6:SUM149 cells have sufficient mitochondria 
Quantification of mitochondria per cell A. Cox 4 protein expression; TEM images of B. MCF-10A cell C. 
MDA-MB-231 cells D. SUM149 Cells E. Mitochondria DNA:  Nuclear DNA ratio. 
 
This chapter represents a “manuscript in progress” and will be submitted for publication 
under the title “Alternative pathway for acetyl CoA metabolism prevents inflammatory 
breast cancer cell line SUM149 from undergoing oxidative phosphorylation” 
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Unbiased metabolomic screening reveals key metabolic pathways responsible for 
energy switch from proliferation to motility in breast cancer cells 
 
Abstract 
Understanding the switch that cancer cells undergo from a proliferation 
predominant phenotype to a motility predominant phenotype required for metastasis is an 
important step towards preventing metastasis.  These studies require a model in which the 
switch from proliferation to motion is modulated in a genetically well-controlled system.  
In previous work in our laboratory, such a model was developed by modulating the 
expression of p38γ.   In this paper, we use the breast cancer cell line MDA-MB-231 
stably transfected with a vector encoding shRNA against mitogen-activated protein 
kinase (MAPK) p38γ or with a vector encoding a shRNA scrambled control.  As is 
demonstrated in the literature, this single molecular change results in increased 
proliferation and decreased motility in this cell line, reverting this aggressive breast 
cancer to a less malignant phenotype.  This body of work uses novel, unbiased 
metabolomic screening techniques to uncover differences in metabolic pathway 
regulation that ultimately leads to modulation of the energy utilization phenotypic switch.   
Introduction 
The MAPK pathway is a key regulator of cellular proliferation, apoptosis, and 
genetic regulation.  The p38 arm of this pathway has been implicated in metabolic 
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diseases and cancer [119].  The p38 protein has 4 different isoforms in humans, α, β, γ, 
and δ.  Isoforms α, β are the most homologous to each other by sequence compared to the 
other isoforms. Likewise, γ and δ are most homologous to each other by sequence.  
Studies have shown that each isoform has unique regulatory properties and do not appear 
to have redundant function [62].  Most of the studies in the literature focus on the α and β 
isoforms, and commonly used inhibitors of p38 are pyridinyl imidazole inhibitors, which 
are specific to the ATPase binding pocket of α and β, and have little effect on the other 
isoforms [64].  Our lab has shown in previous work that MAPK p38γ is an important 
regulator of cellular motility, especially through its interaction with small GTPase RhoC 
[62].  In order to identify the effect that knocking down p38γ in MDA-MB-231 cells has 
on metabolism, we conducted an unbiased metabolic screen to measure the relative 
concentrations of metabolites in the p38γ knockdown cells compared to that of the 
scrambled shRNA control cell line.  This work is the first time that a single molecular 
change in an identical genetic background has been examined using unbiased 
metabolomic screening. 
Results 
Knockdown of p38γ causes changes in the relative amounts of a variety of different 
metabolites. 
This screen detected 304 known metabolites.  The compounds detected are 
depicted by red hexagons (Figure IV.1).    The metabolites detected are members of a 
variety of different pathways, showing good representation of the entire metabolome.  
The relative size of the red hexagons shows whether the compound was found to be 
increased or decreased after p38γ knockdown.   Because this experiment is not a time 
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course, it is important to be aware that a decrease in a particular compound could indicate 
one of two mechanisms: either that the cell is not making as much of this metabolite (due 
to overall pathway down regulation, or a decrease in synthesizing enzyme, etc.) or the 
cell is using more of this particular compound such that the pool size in the cell is low 
(due to overall pathway upregulation, or increase in a catabolizing enzyme, etc.).  
Likewise if a metabolite is increased, it could indicate that the cell is making more of the 
particular compound or that it is not being used up by the cell, so a larger pool is allowed 
to accumulate.  In order to tease out which of the possible scenarios are occurring, further 
experiments including changes over time as well as functional assays will have to be 
done.  The unbiased metabolic screen found changes in a few specific pathways 
highlighted below.   
Knockdown of p38γ causes increases in metabolites in the nucleotide synthesis pathway. 
This screen identified metabolites belonging to the nucleotide synthesis pathways 
that are significantly increased in p38γ knockdown cells.   Metabolites in both purine and 
pyrimidine synthesis are increased in p38γ knockdown cells, (Figure IV.2A, 2B).  
Because it is important for the rapidly proliferating cell to generate the nucleotides 
needed for DNA synthesis to copy its genome the daughter cell, it is likely that the 
increase we see in these metabolites is due to upregulation of nucleotide synthesis in p38γ 
knockdown cells.  
Knockdown of p38γ causes increases in metabolites in the NADH synthesis pathway 
Knockdown of p38γ causes an increase in metabolites involved in the NADH 
synthesis pathway (Figure IV.3A). NADH is an electron carrier and is required to provide 
energy in reduction-oxidation (redox) reactions.  Many metabolic pathways require 
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NADH (or NAD+) to provide (or take up) electrons including glycolysis and oxidative 
phosphorylation.  Because of the increased needs of the replicating cells, NADH 
synthesis may be increased to provide the needed reducing power.  
Knockdown of p38γ causes a decrease in metabolites in the C-21 steroid hormone 
biosynthesis pathway. 
Knockdown of p38γ decreased the relative abundance of C-21 steroid hormone 
biosynthesis pathway (Figure IV.3B). The C-21 steroid hormone pathway is important 
not only for the synthesis of a variety of signals required for growth and proliferation, but 
also is involved with the production of precursors for lipid molecules within the plasma 
membrane [120].  These may be involved in the direction of energy into motility, as 
changes in the cell cytoskeleton and membrane provide the force that allows the cell to 
move.  Because of the known importance of steroid hormones in certain types of cancer 
[121-125], we chose to focus on the C-21 steroid hormone pathway for further study. 
Inhibition of the C-21 steroid hormone pathway with cortisone leads to decreased 
proliferation 
Because p38γ knockdown was shown in previous work to lead to a reversion of 
the very aggressive MDA-MB-231 breast cancer cell line to a less aggressive phenotype, 
we hypothesized that the decreased amount of metabolites seen in the C-21 pathway was 
due to downregulation of the pathway, not increased usage of the pathway.  To see if 
regulation of this pathway is important for the switch from a proliferative to motile state, 
we perturbed this pathway with cortisone.  We hypothesized that the addition of cortisone 
would cause an increase in the C-21 steroid hormone biosynthesis pathway and lead to 
decreased proliferation. We found that concentrations of 4 uM cortisone were able to 
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effectively decrease cell proliferation in p38γ knockdown cells to that of the untreated 
scrambled control cells (Figure IV.4A). Concentrations above 10 uM were lethal to the 
cells (not shown).   
Discussion 
In this study, we examined the aggressive breast cancer cell line MDA-MB-231 
and the effects of a single molecular change, the knockdown of MAPK signaling pathway 
member p38γ on metabolic pathways. Knockdown of p38γ induced a behavioral change 
in the cells from a highly motile state to a highly proliferative state.   We hypothesized 
that p38γ knockdown affected the regulation of metabolic pathways so as to induce a 
metabolic switch redirecting the energy from motility use to proliferation use.    
Knockdown of p38γ was found to induce significant changes in the following pathways: 
nucleotide synthesis, NADH synthesis, and C-21 hormone synthesis.   
Nucleotide synthesis is very important in the rapidly dividing cell, because of the 
need to replicate the cellular genome before cell division [126].  The highly proliferative 
p38γ knockdown cells displayed increased synthesis of nucleotides. NADH synthesis was 
also found to be increased in p38γ knockdown cells, suggesting an increased need for 
cellular reducing power.  
We also found that the steroid hormone biosynthesis pathway was decreased in 
p38γ knockdown cells, suggesting a decreased need for these metabolites in the rapidly 
dividing cell.  Upon the addition of cortisone to the cells, we found that they had 
decreased proliferation.  Additional experiments will need to be performed to see if 
treatment with cortisone will also increase proliferation, which would indicate a reversion 
back to the parent/scrambled control state.  If so, inhibition of the C-21 steroid 
82 
 
biosynthesis pathway may prevent metastasis, or revert aggressive breast cancers to a less 
aggressive phenotype.  Estrogen, a steroid hormone important in normal breast growth 
and maturation, binds to estrogen receptor (ER).  This causes ERs to dimerize and 
activate a signaling pathways that results in the activation or suppression of a variety of 
genes via transcription factors.  In addition, estrogen has been shown to induce cross talk 
affecting both the Her2/Neu pathway as well as the MAPK pathway [121, 123, 127]. 
Dysregulation of steroid hormones can lead to inflammation and cancer, often leading to 
hormonal cancers including breast, ovarian and prostate cancers.  Additionally, recent 
work has shown that the MAPK pathway inhibits the activity of hydroxysteroid (11-β) 
dehydrogenase 2, an enzyme which is encoded by the gene HSD11B2, and converts 
cortisol to cortisone.  Cortisol plays a crucial role in the activation of both glucocorticoid 
and mineralocorticoid receptors.  These receptors regulate a wide range of activities 
including immune suppression and sodium and potassium ion homeostasis.  Cortisol, 
once hydroxylated via HSD11B2 enzyme, becomes cortisone, a much less potent 
activator of these receptors.  The activity of ER crosstalk with the MAPK pathway, as 
well as the inhibitory activity of MAPK on HSD11B2 has suggested a model in which 
knockdown of p38γ prevents crosstalk of these pathways and prevents inhibition of 
HSD11B2 (Figure IV.5).  This results in less of the active cortisol being present in the 
cell, as observed in Figure IV.3B. Due to this, the cells lose the ability to move, and begin 
to proliferate rapidly.  However, when additional cortisone is added, and due to the 
activity of HSD11B1, which catalyzes the opposite reaction, more active cortisol is 
available.  This then may rescue the motility and invasion of these cells. 
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This study shows that the p38 pathway widely affects a variety of metabolic 
pathways.  The elucidation of the signaling between p38 and metabolic signaling 
pathways like mTOR and PI3K/AKT is just beginning to be studied in the literature.  
Understanding the crosstalk of these pathways may result in further understanding of how 
cancer cells dysregulate their proliferation rate and motility. 
 This study identified three other pathways that were significantly altered with 
p38γ knockdown.  Studying the purine, pyrimidine, and NADH pathways may help to 
understand further what metabolic changes occur when a cell switches from a highly 
proliferative to a highly motile state.  
Methods 
Cell Culture 
Stably transfected MDA-MB-231 cells were cultured in RPMI 1640 media 
supplemented with 10% FBS, 5% Pen-Strep, and 5% fungizone with antibiotic selection 
with 1 µg/mL puramycin under 5% CO2 at 37°C.  Media was changed every 3-4 days, 
and cells were passed upon reaching confluence. 
MTT assay 
Cells were plated in replicates of six in six 96 well plates, 1000 cells per well.  
Cells were allowed to adhere to the plates, and then were serum starved overnight (12-
18hours) to synchronize. Serum free media was replaced with growth media with 0, 4 or 
4.5 uM cortisone.  Timepoints were taken at 0, 1,2,3,4,5,6,7 days after treatment with 
cortisone.  For each timepoint, 50 µL of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was added to each well.  After 1 hour incubation at 37°C, 
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media and MTT solution was removed from each well.  100 µL DMSO was then added 
and the plate was shaken for 5 min.  Absorbance was read at 595 nm.    
Bead Motility Assay 
Cells were serum starved overnight and then treated for 24 hours with 0, 4, or 4.5 
uM cortisone and then plated on a field of fluorescent beads and incubated overnight.  
Cell tracks were quantified using ImageJ. 
Treatment of cells with cortisone 
Cells were treated with 0, 4, 4.5 uM cortisone for 24 hours. Concentrations 
greater or equal to 10 uM were found to kill the cells.  Measurement of proliferation and 
motility assays were conducted as before. 
Preparation of Extracts for Unbiased Metabolomic Screening 
Cell extracts were prepared and analyzed according to a modified protocol from 
Lorenz et al, (Lorenz, 2011). 13 x 10cm plates for each cell line were grown for 2-3 days 
to 80% confluence on collagen coated plates in standard growth media.  The plates were 
changed to fresh growth media one hour before quenching with liquid nitrogen.  Three 
plates from each cell line were reserved for protein normalization.  After the one hour the 
remaining ten plates were then rinsed by rapid addition and removal of 4 mL of distilled 
water, after which metabolism was immediately quenched by pouring liquid nitrogen into 
the plate. Plates were stored at -80°C until extraction.   Cells were extracted by adding 1 
mL of ice-cold 8:1:1 methanol:water:chloroform containing 18 µg/mL of a 13C amino 
acid mix (Sigma, part 426199) to serve as an internal standard to the frozen cell surface 
and scraping with a cell scraper. The extract and residual cell debris were transferred to 
polypropylene microcentrifuge tubes and centrifuged for 5 min at 15,000 x g at 4°C.  The 
85 
 
supernatant was transferred to autosampler vials and analyzed by LC-MS.   Following 
centrifugation, 500 µL of supernatant was dried under nitrogen and reconstituted in 250 
µL of water containing tert-butyloxycarbonyl-protected amino acids to serve as injection 
standards.    
LC-MS Methods and Data Analysis 
For targeted metabolomics, samples were analyzed on an Agilent 1200 LC / 6520 
qTOF MS system.  To obtain good retention of the polar, predominantly anionic 
metabolites of glycolysis and the TCA cycle, chromatographic separation was performed 
by mixed mode hydrophilic interaction – anion exchange using a Luna NH2 3µ column, 
150 mm x 1 mm ID (Phenomenex, Torrance, CA).  Mobile phase A was acetonitrile and 
mobile phase B was 5 mM ammonium acetate in water, adjusted to pH 9.9 using 
ammonium hydroxide.  The gradient was a 15 minute linear ramp from 20 to 100%B, 
followed by a 5 minute hold at 100%B and a 17-minute requilibration period at 20%B.  
The column temperature was 25°C and the flow rate was 0.07 mL/min, which was 
ramped to 0.09 mL/min between 20 to 32 minutes.  The injection volume was 10 µL.  
Electrospray ionization was carried out in negative ion mode using a source gas 
temperature of 350° C, a drying gas temperature of 10 L/min, a nebulizer pressure of 20 
psig, and a capillary voltage of 3500 V.  Data were collected in TOF full-scan mode over 
m/z 50-1200 at an acquisition rate of 1 spectra/s with reference mass correction enabled.  
Data were analyzed using Masshunter Quantitative Analysis software.  Metabolites and 
their 13C isotopes were identified by retention time and m/z values determined from 
authentic standards.  Quantification was performed by peak area after manual inspection 




For unbiased metabolomics, samples were analyzed on an Agilent 1200 LC / 
6530 qTOF MS system using a Waters Acquity HSS T3 reversed-phase column, 50 mm 
x 2.1 mm ID.  For positive ion mode runs, mobile phase A was water with 0.1% (v/v) 
formic acid and mobile phase B was methanol with 0.1% formic acid.  For negative ion 
mode runs, the formic acid was replaced with 0.1% (m/v) ammonium bicarbonate.  The 
gradient was as follows: 0-0.5 min 1% B, 0.5-2 min 1-99% B, 2-6 min 99% B, 6-6.1-9 
min 1% B.  The flow rate was 0.35 mL/min and the column temperature was 40° C.  The 
injection volumes for positive and negative mode were 5 and 8 µL, respectively.    ESI-
MS conditions were the same as for targeted analysis except that the Agilent Jetstream 
source was used, the nebulizer pressure was 30 psig, and the sheath gas temperature and 
flow rate were 350° C and 11 L/min.  Data analysis was performed using a two-step 
approach using Agilent Masshunter Qualitative Analysis Software. First, known 
compounds were identified by searching the LC-MS data against an in-house metabolite 
library of approximately 600 previously-analyzed authentic standards using the find by 
formula algorithm.  Then, the molecular feature extractor algorithm was used to detect 
additional unknown features, the features were aligned between samples by mass and 
retention time, and finally these features were selected and quantitated using find by 
formula.  Principle component analysis was applied to the data to rank features in order 
of their contribution to differences in the metabolome between cell types. 
Protein Normalization of Mass Spectrometry Data 
Three additional plates were grown up in each experiment per cell line.  Cells 
were rinsed twice with cold PBS, and then treated with RIPA buffer with complete 
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protease inhibitor cocktail (Roche) added at suggested concentration for 25 minutes with 
gentle agitation at 4°C.  Protein was scraped off the plate and sheared with a 23-gauge 
syringe 3-4 times.  Protein was collected in microcentrifuge tubes and spun for 15 
minutes at 13,000 rpm at 4°C to pellet cellular debris.  A Bradford assay was performed 
to quantify the amount of protein in each sample.  This data was averaged and used to 
normalize the mass spectrometry data to account for differences in the growth rate of 
cells. 
Validation of Unbiased Screening 
Directed metabolomic studies were performed as described above to validate 
pathways in which changes were observed in the unbiased screening experiment. 
Data Analysis 







Figure IV.1: Unbiased metabolic screening yields information about pathway changes upon p38γ 
knockdown 
Metabolic map of data. Red hexagons represent compounds that were detected; blue hexagons represent 
compounds filled in by Metscape data program.  Relative size of hexagons indicate whether compounds 
was found in increased or decreased abundance in p38γ knockdown cells compared to scrambled control. 





Figure IV.2: Nucleotide synthesis pathways are altered upon p38γ knockdown 
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Figure IV.4: Addition of cortisone lowers proliferation back to normal levels 
A. MTT Cellular Proliferation Assay 
  
A 
231GKD, 0.0 μM Cortisone
231GKD, 4.0 μM Cortisone
231GKD, 4.5 μM Cortisone
231SCR, 0.0 μM Cortisone
231SCR, 4.0 μM Cortisone

























Figure IV.5: Model of Cortisone Regulation 
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Conclusions and Future Directions 
 
Conclusions 
Understanding the changes that occur in cancer cells that allow them to leave their 
area of origin and locally invade and metastasize is crucial in order to target this process 
and reduce mortality.  In the literature, the process of metastasis has been studied in the 
context of identifying cancer stem cells that can generate metastatic cells, as well as the 
epithelial to mesenchymal transition (EMT) which enables some cell types to gain 
metastatic capabilities.  Studying the process of metastasis from a metabolic viewpoint 
has provided new insights into the process by which aggressive cancer cells acquire this 
ability.  In these studies, we utilized breast cell lines to examine the metastatic process.  
We used immortalized normal breast epithelial cells (MCF-10A), aggressive and 
metastatic breast cancer cells (MDA-MB-231) and inflammatory breast cell line 
(SUM149), which are also metastatic.  Using these two very different metastatic cell lines 
enabled us to determine some of the different mechanisms that cells use to acquire 
metastatic properties.  This work identified the mevalonate pathway, an alternative 
acetyl-CoA metabolic pathway, and the C-21 steroid hormone biosynthesis pathways as 
important regulators of motility and metastasis.  In the following section, I will discuss 
the important conclusions of each chapter. 
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Chapter II: Zoledronic acid treatment prevents phosphorylation of CUB-domain 
containing protein 1 and leads to decreased motility and invasion in breast cancer 
In this chapter, we found that the mevalonate pathway is important in the 
regulation of prenylation and activation of small GTPases including RhoC, Cdc42, and 
Rac.  These small GTPases are critical in the regulation of cell movement through actin-
myosin contractility and are part of the process necessary for invasion and metastasis. 
The mevalonate pathway synthesizes and attaches prenyl groups to these small GTPases, 
which targets them to their site of activity, the cell membrane.  Recent work in our lab 
has shown RhoC to be required for metastasis, thus the role of the mevalonate pathway in 
targeting of Rho C to the cell membrane is vital [128].  Mevalonate pathway inhibitors 
atorvastatin (AT), zoledronic acid (ZA) and geranylgeranyl transferase inhibitor 298 
(GGTI) were all able to reduce the ability of breast cancer cells to move and invade to 
differing extents.  ZA was found to be not as effective as the other mevalonate pathway 
inhibitors in most of the in vitro assays conducted, usually only affecting MDA-MB-231 
breast cancer, and not the SUM149 breast cancer cell line, perhaps due to its inability to 
affect the localization of the small GTPases (Figure II.5).  Because we observed that ZA 
was effective in some of the assays, but did not affect GTPase localization as 
hypothesized, we conducted a microarray to look for alternative targets that ZA could be 
affecting.  Among the many genes in the microarray that showed differential expression 
after ZA treatment, we selected CUB-domain containing protein 1 (CDCP1) for further 
study because it has been proposed in the literature to regulate invasion and motility in 
cancer and to interact with the AKT pathway [97, 98].  From this, we identified CUB-
domain containing protein 1 (CDCP1) as an important target of ZA.  We identified a 
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novel mechanism in which ZA inhibits the phosphorylation, and thus activation of 
CDCP1.  CDCP1 plays a very important role in the regulation of motility and invasion, 
presumably through interaction with the AKT pathway [95, 98].  Other labs have studied 
the effect of the mevalonate pathway in breast cancer motility and invasion, and our 
results are consistent with the literature [86, 89-91] 
Chapter III: Alternative pathway for acetyl CoA metabolism prevents inflammatory 
breast cancer cell line SUM149 from undergoing oxidative phosphorylation 
 In our work studying inflammatory breast cancer, we discovered that SUM149 
cells do not undergo oxidative phosphorylation.  While it has been extensively shown in 
the literature that cancer cells undergo the Warburg effect[2, 4, 10, 16, 17, 26, 115], such 
a severe phenotype in which cancer cells are unable to undergo oxidative phosphorylation 
and do not consume oxygen has not been seen, except in cells that lack mitochondria 
entirely (Human 143B osteosarcoma ρ° cells) [129].   In the Warburg effect, cancer cells 
preferentially use the process of glycolysis alone to metabolize glucose to lactic acid and 
2 molecules of ATP, even in the presence of excess oxygen, instead of metabolizing 
glucose to enter the TCA cycle and then oxidative phosphorylation, breaking it down to 
CO2 and 32-36 molecules of ATP [16, 130].  In this paper, we found that SUM149 cells 
had sufficient numbers of morphologically normal mitochondria (Figure III. 7).  
Additionally, while SUM149 cells expressed reduced protein levels of both citrate 
synthase and pyruvate dehydrogenase, which both had reduced catalytic activity in vitro 
(Figure III.3), this was not sufficient to explain the phenotype in the cells.  After 
completing both directed and unbiased metabolomics studies, an alternate pathway for 
acetyl-CoA metabolism in the SUM149 cell line was identified.  Normal cells will use 
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pyruvate derived-acetyl CoA to make citrate, beginning the tricarboxylic acid (TCA) 
cycle.  This pathway eventually breaks down the six carbon citrate to four carbon 
oxaloacetate, releasing two molecules of carbon dioxide (CO2) as well as producing two 
molecules of nicotinamide adenine dinucleotide (NADH) and one molecule of flavin 
adenine dinucleotide (FADH2) (Figure I.3).  NADH and FADH2 act as reducing agents, 
carrying electrons that are used as an energy source for the electron transport chain. 
Besides these electrons, the oxidative phosphorylation also requires oxygen consumption.  
However, in SUM149 cells, we found that they did not use pyruvate-derived acetyl CoA 
for citrate synthesis, but instead use it to make N-acetyl-aspartate.  It is unclear at this 
time where the synthesis of N-acetyl aspartate is the cause of these cells inability to 
undergo oxidative phosphorylation or an effect of this inability.  We propose, however, 
that the production of N-acetyl aspartate leads to a deficiency in citrate.  Because of the 
lack of citrate to run the TCA cycle, it may be that the cells cannot produce enough of the 
TCA cycle intermediates necessary for oxidative phosphorylation.  This inability to 
perform oxidative phosphorylation may confer the ability to survive and thrive under 
hypoxic conditions to SUM149 cells, thereby facilitating metastases.  In fact, recent work 
has shown that SUM149 cells are constitutively adapted to hypoxia via constitutive 
upregulation of hypoxia inducible factors (HIFs) [131].  Our work suggests a mechanism 
which allows SUM149 cells to prevent reliance on oxidative phosphorylation, reducing 
its need for oxygen consumption. We hypothesize that siRNA knockdown of acetyl 
transferase enzyme encoded by N-acetyl-aspartate transferase 8-like (NAT8L), which 
synthesizes N-acetyl aspartate from acetyl-CoA and oxaloacetate, will restore the ability 
of SUM149 cells to undergo oxidative phosphorylation.  Additionally, overexpression of 
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aspartoacylase (ASPA) enzyme necessary to break down N-acetyl aspartate may also 
rescue this phenotype.  These experiments will also allow us to determine if N-acetyl 
aspartate synthesis is the cause of the oxidative phosphorylation defect or if it is an effect.   
Chapter IV: Unbiased metabolomic screening reveals key metabolic pathways 
responsible for energy switch from proliferation to motility in breast cancer cells 
 In this study, we examined the role of p38γ in the regulation of proliferation and 
motility in the aggressive, metastatic breast cell line MDA-MB-231.  Previous work in 
our lab showed that shRNA knockdown of p38γ resulted in a reduction of cellular 
motility and an increase in proliferation in these cells [62].  Further work showed that 
p38γ regulates the stability of small GTPase motility protein RhoC, and that p38γ 
knockdown resulted in the formation of abnormal actin structures, thus inhibiting the 
ability of these cells to move in a productive manner [62].  The p38γ knockdown cells 
acted like a less aggressive cancer in every in vitro measure of metastatic potential, 
suggesting that p38γ is an important factor in breast cancer aggressiveness [62].  Further 
work in a murine xenograft model showed that p38γ knockdown cells formed larger 
tumors that grew more quickly than the scrambled control cell line [unpublished data], 
but they also metastasized significantly less frequently [62].   
In total, these studies suggest that p38γ may regulate an important metabolic 
switch that selects whether energy should be used to proliferate or to move.  This switch 
may be crucial in understanding what occurs in the process of metastasis in terms of 
factors involved in the cell when it begins to reactivate motility programs in order to 
metastasize.  In this work, through the use of unbiased metabolic screening, we have 
identified C-21 steroid hormone biosynthesis as being essential for the metabolic switch 
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between proliferating and motile cellular behaviors.  This pathway, through the 
generation of hormones such as estrogen and testosterone, plays a key role in the 
regulation of cancers of the reproductive system including breast, ovarian, and prostate 
cancers.  In this chapter, we found that C-21 steroid hormone biosynthesis was decreased 
in MDA-MB-231 when p38γ was knocked down.  We hypothesized that the addition of 
cortisone, an important member of this pathway and precursor to hormones such as 
estrogen, may rescue the effects of p38γ knockdown.   We found that the addition of 
cortisone did slow the proliferation rate of p38γ knockdown cells back to the level of the 
scrambled control.  Further experiments will need to be done to find out if cortisone 
addition can also rescue the motility defect in p38γ knockdown cells.    The results of 
these experiments suggest the importance of the C-21 steroid hormone biosynthesis 
pathway in the regulation of the switch from proliferation to motility in the cancer cell. 
 The final portion of this chapter will discuss future directions for each of the 
research findings. 
Future Directions 
Chapter II: Zoledronic acid treatment prevents phosphorylation of CUB-domain 
containing protein 1 and leads to decreased motility and invasion in breast cancer 
In this chapter, the effect of the mevalonate pathway in modulating motility and 
metastasis in breast cancer and normal breast cells was examined.  The mevalonate 
pathway was found to play an important role in regulating cell shape, individual motility, 
collective cell motility, and invasion.  In addition, an alternative mechanism of action for 
zoledronic acid (ZA) was identified.  ZA prevents the tyrosine phosphorylation and thus 
activation of CUB-domain containing protein 1 (CDCP1).  This protein plays important 
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roles in cancer, especially in regulating metastasis and invasion processes.  Further work 
to fully characterize the role of ZA in the inhibition of CDCP1 activation will be 
necessary in order to uncover the details of this mechanism.  The exact mechanism of the 
inhibition of CDCP1 by ZA has yet to be determined.  Perhaps ZA prevents 
phosphorylation by directly binding to CDCP1, causing a conformational change so that 
the tyrosine residue is no longer accessible for phosphorylation. Alternatively, ZA could 
bind to the src-family kinase responsible for phosphorylation of CDCP1.  Teasing out this 
mechanism could be accomplished by analyzing how ZA affects the expression or 
prevents binding of src-family kinases to CDCP1.  To determine if ZA directly binds 
CDCP1, isothermal titration calorimetry could be conducted with varying amounts of ZA 
to measure the binding affinity and thermodynamic properties[132].  Also, CDCP1 is an 
important activator of the AKT/MAPK pathway [97, 98]. To see if the inhibition of 
CDCP1 via ZA affects the AKT pathway, measuring AKT activation via phosphorylation 
of AKT isoforms AKT1, AKT2, and AKT3 will be important.   This can be accomplished 
using AKT1, 2, and 3 specific antibodies to pull down these proteins, and then Western 
blotting with a pan-Phospho-AKT antibody.   
The present paper found that ZA did not change the localization of small GTPase 
proteins as hypothesized due to its proposed role in mevalonate pathway regulation via 
inhibition of farnesyl pyrophosphate synthase.  Because of this, a microarray was 
conducted in order to identify possible targets of ZA.   Further validation and study of 
this data may lead to more complete knowledge of the effect of ZA on breast cancer cells.  
Although we did not validate every hit, in Chapter II, we focused on CDCP1 because of 
its importance in cancer motility. One other target that we pursued is methionine 
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transferase 2A (MAT2A) because of our interest in metabolism.  MAT2A is the gene for 
a subunit of the MAT II complex, which is responsible for the production of s-adenosyl 
methionine (SAM) from methionine and ATP [133].  SAM is a potent anti-proliferation 
signal that acts to regulate MATII, thereby preventing further SAM production.  MAT2A 
protein expression is decreased in the two cancer cell lines compared to normal cells, 
which is the anticipated result, given its anti-proliferative role.  ZA treatment further 
reduced the expression of MAT2A in the cancer cells (Figure V.1A).  MAT2A has been 
shown to play an important role in breast cancer as the methyl donor for DNA 
methylation, which often occurs in breast cancer [134].  Inhibitors of SAM in breast 
cancer cells are very effective antitumor agents, possibly acting through activation of 
MAPK and STAT signaling [135].  In our proposed model, ZA acts on MAT2A, 
reducing the amount of SAM available for DNA methylation, and activates MAPK and 
STAT pathways, leading to reduced invasion and proliferation (Figure V.1B).  It will be 
important to further identify the role of ZA in MAT2A regulation by measuring DNA 
methylation, as well as JAK/STAT pathway activation upon ZA treatment. 
In addition to the target MAT2A, we identified 10 other targets that we were able 
to verify via qRT-PCR (Figure II.9).  These targets, listed in Table V.1A, need to be 
examined further.  Additionally, we found in this work that ZA often had opposite effects 
in the two breast cancer cell lines MDA-MB-231 and SUM 149 (See Chapter II).  In 
agreement with that work, we identified several targets in the microarray that were 
differentially regulated upon ZA treatment between these two cell lines.  These genes are 
listed in Table V.1B, and may help to uncover the differential mode of action of ZA in 
these two breast cancer cell lines. 
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Due to the number of targets identified in the microarray, this drug may have 
many non-specific, off-target effects.  Further work characterizing commonalities among 
the drug targets to identify how ZA interacts with each target, perhaps through a specific 
binding motif, could lead to information that may help in the generation of more specific 
drugs. Additionally, work to improve the specificity of other mevalonate pathway 
inhibitors, such as GGTIs or FTIs (farnesyl transferase inhibitors) may lead to less toxic 
therapies that may prove very effective in the clinic. 
Chapter III: Alternative pathway for acetyl CoA metabolism prevents inflammatory 
breast cancer cell line SUM149 from undergoing oxidative phosphorylation 
This work identified an alternate pathway for acetyl-CoA metabolism in the 
inflammatory breast cancer cell line SUM 149.  In this pathway, acetyl-CoA is redirected 
from the synthesis of TCA cycle intermediate citrate and is instead used to acetylate 
aspartate, making N-acetyl aspartate.  This metabolite has no known function outside of 
the nervous system.  If most of acetyl-CoA is directed into N-acetyl aspartate synthesis, 
then very little will be available for use in the TCA cycle to generate intermediates 
necessary for oxidative phosphorylation.  This may explain a least part of the oxidative 
phosphorylation defect in SUM149 cells. We found that the acetyltransferase enzyme 
NAT8L, which forms N-acetyl aspartate from aspartate and acetyl-CoA, is highly 
upregulated at the mRNA level in SUM 149 cells (III.4D).  In addition, the deacetylating 
enzyme ASPA, which converts N-acetyl aspartate back to acetic acid and aspartate, is 
absent at both the mRNA and the protein level in SUM 149 cells (III.4D, E).  We 
hypothesize that either knockdown of NAT8L or overexpression of ASPA enzymes may 
be able to rescue at least part of the oxidative phosphorylation defect in SUM149 cells.  
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Additionally, overexpression of NAT8L in normal breast cells MCF-10A may induce a 
reduction in their oxidative capacity.   Other work has shown that SUM 149 cells are 
constitutively adapted to hypoxia [131].  If the production of N-acetyl aspartate does 
prevent oxidative phosphorylation, the ability to make this metabolite may account for a 
large portion of this phenotype.  This study highlights the importance of this enzyme and 
metabolite in the aggressiveness of SUM 149 cells.   
 Further work should be done to determine if accumulation of N-acetyl aspartate is 
specific to only SUM149 cells, or if it can be generalized to aggressive breast cancers or 
cancer as a whole.  In our studies, we did find that aggressive breast cancer cell line 
MDA-MB-231 was also able to make N-acetyl aspartate, but only accumulated about half 
that of what SUM149 cells did (Figure III.4A, B).  Also, the mRNA and protein 
expression of NAT8L was much lower in MDA-MB-231 cells (Figure III.4D). However, 
because MDA-MB-231 cells express ASPA protein, (Figure III.4 E), we hypothesize that 
they can efficiently break down N-acetyl aspartate, allowing these cells to retain the 
ability to perform oxidative phosphorylation (Figure III.1A). Recent work has also shown 
an accumulation of this metabolite in human ovarian cancer samples, with higher 
amounts in metastatic compared to epithelial ovarian tumors [136].  Staining tumor 
samples with NAT8L antibodies may show a correlation of higher expression of NAT8L 
with more aggressive tumors and may be associated with poor clinical outcomes.  
 Other work has shown the correlation of N-acetyl aspartate with inflammation 
[137].  Inflammation is an important component of the development and progression of 
cancer [138, 139], and the role of this metabolite in either inducing or sustaining 
inflammation may be an important area to investigate.  There is a large body literature 
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regarding tumor associated macrophages (TAMs), and their role in the cancer 
microenvironment. TAMs have been found to play both tumor-promoting and tumor-
inhibiting roles.  TAMs have been found to play cancer promoting roles by secreting 
cytokines which provide cancer cells with growth and migration signals, as well as 
recruiting more immune cells to the area to produce even more cytokines[139].  
Additionally, TAMs can secrete angiogenic factors like vascular endothelial growth 
factor (VEGF) that aid the cancer cells in making new blood vessels to provide a greater 
oxygen and nutrient supply[140, 141].  Also, TAMs can secrete matrix metalloproteases 
(MMPs) which can aid the cell in the invasion process, and they can secrete additional 
cytokines that activate the MMPs [141]. TAMs have also been shown to have an 
anticancer effect, as in gastric cancer and non-small cell lung cancer, infiltration of the 
tumor with TAMs correlates with improved prognosis [138, 142, 143].   These cells may 
play an important role in mediating the inflammatory effect of N-acetyl aspartate.  
Further study into how N-acetyl-aspartate may regulate inflammation in the context of 
breast cancer and how TAMs may mediate this effect should be pursued.  Co-culturing 
SUM149 cells with TAMs may enable us to identify an effect of N-acetyl aspartate as 
well as uncover any role that TAMs may play in promoting an inflammatory 
microenvironment due to increased cytokine and pro-angiogenic factor secretion ([139-
141]) 
 Because of the lack of knowledge of the function of N-acetyl aspartate outside the 
brain, further work should be done to examine its presence in both tumor and normal 
tissue samples.  If, indeed it is not found in normal non-brain tissue, this may make an 
ideal drug target.  The blood-brain barrier is highly selective and prevents toxins and 
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chemicals from reaching the brain.  A drug that was manufactured to target NAT8L or N-
acetyl aspartate could be engineered so that it would not pass through the blood-brain 
barrier and affect normal brain function.  Wiame et al. [114] developed a radiochemical 
in vitro assay that can measure NAT8L activity, and Tahay et al. [113] modified the 
assay to use DNTB [5,5-dithiobis-(2-nitrobenzoic acid)] as an indicator for a colorimetric 
in vitro assay to measure activity.    This assay could be coupled with a small molecule 
screen to look for molecules that inhibit NAT8L activity.   
 When we first observed the inability of SUM 149 cells to undergo oxidative 
phosphorylation (Figure III.1B), we hypothesized that these cells were unable to transport 
pyruvate into the mitochondria.  We first conducted 13C-2,3-pyruvate stable isotope 
tracing experiments in order to determine if pyruvate was entering into the mitochondrial 
TCA cycle.  These experiments showed low amounts of citrate being labeled by pyruvate 
in SUM149 cells, as well as low unlabeled citrate (Figure III.3C), which seemed to 
confirm this hypothesis.  To observe the role of the mitochondrial transporter directly, we 
performed these same 13C-2,3-pyruvate stable isotope tracing experiments with and 
without the phenyl succinate, which inhibits this transporter.  We found that inhibition of 
the transporter had similar effects on all three cell lines, and led to decreased amounts of 
labeled substrate in TCA cycle intermediates, consistent with its role of inhibiting the 
mitochondrial pyruvate transporter (Figure V.2).  This data was unable to explain the lack 
of oxidative phosphorylation in SUM149 cells, as we would have expected to see a much 
stronger effect of phenyl succinate in MCF-10A and MDA-MB-231 cells, and little to no 
effect on SUM 149 cells if their mitochondrial pyruvate transporter was not functional.  
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After additional examination of the 13C-2,3-pyruvate stable isotope tracing experiments, 
we found that although there were low amounts of unlabeled and labeled citrate in SUM 
149 cells, acetyl-CoA was being efficiently made in these cells (Figure III.3B), which 
suggests that there is no defect of the mitochondrial pyruvate transporter.  
Because of the high rate of glutamine degradation in cell media [144] and the 
known importance of glutamine as a TCA cycle substrate in cancers through the process 
of glutaminolysis [26, 115], we decided to investigate whether there was sufficient 
glutamine in the media we were using to conduct both the bioenergetic profile 
experiments to measure oxidative phosphorylation as well as the 13C-2,3-pyruvate stable 
isotope tracing experiments.  The same media is used for both, and when we quantified 
the amount of glutamine in media samples saved and frozen from a 13C-2,3-pyruvate 
stable isotope tracing experiment, we found that the levels of glutamine were much lower 
than that of the expected 2.5 mM, and were lower than the published km of 3 mM for 
glutaminase, the enzyme which converts glutamine to glutamate for preparation of its 
entry for use as a TCA cycle fuel (See Table V.2 and Figure I.3) [145].  If glutamine 
concentrations are low, glutaminolysis is probably not occurring in the cell lines.  If there 
is a block in the TCA cycle early between acetyl-CoA and citrate, and this causes 
deficient oxidative phosphorylation due to the inability to produce TCA cycle 
intermediates necessary for this process, providing glutamine for glutaminolysis may 
rescue this phenotype.  Because of this, I decided to measure oxidative phosphorylation 
in SUM149 cells with and without glutamine.  In this experiment, I found that in both 
cases, SUM149 had very low rates of oxygen consumption and did not respond to any of 
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the mitochondrial inhibitors, showing that the inability of SUM149 cells to undergo 
oxidative phosphorylation is a glutamine-independent phenotype (Figure V.3). 
It is important to note that due to the low amounts of glutamine that I observed in 
the media (Table V.2), all of my 13C-2,3-pyruvate stable isotope tracing experiments may 
have had low glutamine concentrations.  I would expect that if I prepared the media with 
fresh glutamine before the experiment, I may see an increase in the amount of unlabeled 
citrate being made in SUM149 cells; however, I would not expect to see an increase in 
labeled citrate, because the 15-minute incubation time with 13C-2,3-pyruvate would not 
be enough time to label sufficient amounts of glutamine to then be used as a TCA cycle 
substrate.  Completing a13C-2,3-pyruvate stable isotope tracing experiment with and 
without glutamine may also inform us of the importance of glutaminolysis in SUM149 
cells by allowing us to measure the fraction of TCA cycle intermediates that are produced 
with and without the presence of glutamine. 
 In order to directly quantify glutaminolysis in all three cell lines, we also 
performed glutamine tracer experiments with uniformly labeled 13C-glutamine.  Because 
SUM 149 does not appear to use much pyruvate derived acetyl-CoA for the synthesis of 
citrate and other TCA cycle intermediates, we hypothesized that these cells may rely 
more on glutaminolysis in order to generate these intermediates.  We hypothesized that 
cells without glucose will rely more on glutaminolysis for making both energy and 
bioenergetic material, and we would observe a higher percentage of labeling in 
intermediates when no glucose is given.   We found that indeed the SUM 149 cells do 
perform more glutaminolysis than MDA-MB-231 and MCF-10A cells (Figure V.4).  
Additionally, when the cells are not given glucose, they appear to metabolize glutamine 
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more rapidly.  However, the 15 minute timepoint we used may not be the ideal time point 
as it appears that very little glutamine label is getting into the cells.  Further optimization 
is needed to find ideal the time points to detect adequate label incorporation.   
Surprisingly, this work showed that breast cancer cells undergo gluconeogenesis 
(Figure III.3E, F).  To our knowledge, only cells of liver, kidney, or intestinal origin have 
been found to perform gluconeogenesis [27].  This is a paradigm-altering finding.  It may 
be that other cancers also undergo gluconeogenesis, making this process a possible target 
for cancer therapy or a useful biomarker for cancer diagnosis in normally non-
gluconeogenic tissues.  However, due to the prevalence of this process in normal human 
tissues of liver, kidney, or intestinal origin, it may not make an ideal target for therapy.  
Further study will need to be undertaken to understand how and why these cells use this 
mechanism to make glucose from lactate and pyruvate.  Utilizing this process may be 
more efficient than oxidative phosphorylation in terms of energy cost and time to 
complete.  Additionally, in our 13C-2,3-pyruvate stable isotope tracing experiments that 
identified gluconeogenesis in our cell lines, we were unable to quantify glucose 
production, just labeled glycolysis intermediates upstream of pyruvate including fructose- 
1,6-bisphosphate, 2-phosphoglycerate, and 3-phosphoglycerate (Figure III.3, I.4).  It may 
be that these cell lines are instead using gluconeogenesis only to produce metabolites 
upstream of pyruvate in order to generate intermediates necessary for nucleotide and 
serine synthesis and are not using gluconeogenesis to make more glucose.  Measuring the 
protein expression of gluconeogenesis enzymes (listed in red in Figure I.4) in our cancer 
cell lines to look for which ones are upregulated might give us an idea of whether the 
cells are taking lactate and pyruvate all the way back to glucose or not.  For example if 
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glucose-6-phosphatase expression is low, it would suggest that the cells are not taking 
lactate and pyruvate all the way back to glucose, as this enzyme catalyzes the last step in 
gluconeogenesis, the conversion of glucose-6-phosphate to glucose.  To examine if using 
gluconeogenesis is widespread in cancer, examining the mRNA expression of 
gluconeogenesis enzymes may be informative.  
In order to further understand the differences between the SUM149, MCF-10A, 
and MDA-MB-231 cell lines we conducted quantitative-RT-PCR arrays of mitochondrial 
energy metabolism (Figure V.5, Table V.3).  This led to some interesting observations, 
such as very high expression of lysosomal ATPase pumps in SUM149 cells.  Due to the 
high amount of lactic acid production in this cell line, it may be that these pumps need to 
be utilized in order to pump lactic acid out of the cell.  Further study into the importance 
of these pumps may result in the identification of new targets for this aggressive breast 
cancer.  Additionally, changes in mRNA expression were found in subunits of succinate 
dehydrogenase and NADH dehydrogenase complexes.  These complexes are required for 
oxidative phosphorylation, and further exploration of how their expression might be 
regulated differently in SUM149 cells may lead a more robust description of how these 
cells are unable to perform oxidative phosphorylation. 
Chapter IV: Unbiased metabolomic screening reveals key metabolic pathways 
responsible for energy switch from proliferation to motility in breast cancer cells 
In this chapter we used unbiased metabolomics screening to determine the effect 
of p38γ knockdown on breast cancer cell line MDA-MB-231.  We found previously that 
p38γ knockdown increased proliferation and decreased motility, causing these cells to 
revert to a less aggressive state.  We hypothesized that this single molecular change 
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resulted in the alterations of metabolic pathways leading from the phenotypic switch from 
motile to proliferative cells.  Our screen identified several key pathways that seemed to 
be altered upon p38γ knockdown.  In this chapter we studied the C-21 steroid hormone 
biosynthesis pathway in further detail because of the known importance of steroid 
hormones in breast cancer.  We found that the addition of pathway intermediate cortisone 
rescued the effects of p38γ knockdown by reducing proliferation.  Further work should be 
done to examine the effect of cortisone addition on motility and invasion.  We 
hypothesize that cortisone addition will allow the cells to overcome the motility defect 
and increase invasion.  This work highlights the importance of this pathway in regulating 
the phenotypic switch between proliferation and motility.  Further work will need to be 
done to characterize the mechanism by which p38γ regulates this metabolic pathway.  
 In addition, this work identified alterations in the bile-acid synthesis pathway and 
the NADH synthesis pathway.  Further investigations into both of these pathways may 
help to characterize this phenotypic switch.  In p38γ knockdown cells, the bile-acid 
synthesis pathway seemed to be downregulated overall.  The molecule taurine was 
significantly downregulated in p38γ knockdown compared to scrambled control cells.  
Taurine derivatives have been shown to play a role in the regulation of cancer cell 
proliferation [146]. Experiments stimulating the p38γ knockdown cells with taurine may 
rescue the knockdown phenotype as well.  Additionally, NADH synthesis seemed to be 
upregulated in p38γ knockdown cells.  Inhibiting this process with a small molecule 
inhibitor may rescue the knockdown phenotype.  Additionally, understanding the role of 
p38γ knockdown in the direct or indirect regulation of these pathways should be pursued.  
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 When we first began to tease out the metabolic differences between the p38γ 
knockdown and the scrambled control cells, we conducted a bioenergetic profile to 
measure oxidative phosphorylation.  In the literature, cancer cell lines display reduced 
oxidative capacity (due to a preference for lactate production).  More aggressive cancer 
cells usually display less oxidative capacity than less aggressive cells [147].  We found 
that p38γ knockdown cells displayed a higher oxidative capacity (Figure V.6), which is 
consistent with their less aggressive phenotype. 
Methods 
Cell Culture and drug treatment 
MCF-10A cells were cultured in 1:1 Ham’s F-12 and Dulbecco’s modified 
Eagle’s medium (DMEM) with 2 mM L-glutamine supplemented with 5% horse serum, 
extracellular growth factor, cholera toxin, insulin, hydrocortisone, gentamycin, 
fungizone, and penicillin/streptomycin at 37ºC under 5% CO2. MDA-MB-231 cells were 
cultured in RPMI 1640 supplemented with 10% fetal bovine serum, gentamycin, 
fungizone and penicillin/streptomycin at 37ºC under 5% CO2. SUM149 cells were 
cultured in Ham’s F-12 with L-glutamine supplemented with 5% fetal bovine serum, 
insulin, hydrocortisone, gentamycin, fungizone and penicillin/streptomycin under 10% 
CO2. For drug treatment, all cells were grown to 30-50% confluence, serum starved for 
16-20 hours, then treated with 10μM ZA (dissolved in PBS) for 72 hours total in serum-
containing medium. Medium containing ZA was replaced after 48 hours. Drug 
concentration and treatment times were determined based on what has been previously 
reported in literature [83, 102-105] and results from cell proliferation assays (MTT 
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assays, data not shown). The concentrations used were effective at inhibiting growth of 
MDA-MB-231 and SUM149, but not MCF10A cells.  
Protein Extraction and Western Blot 
Cells were washed with cold phosphate-buffered saline (PBS) and lysed in 
radioimmunoprecipitation assay (RIPA) buffer plus Complete protein inhibitor cocktail 
(Roche).  Cells were sheared with a 23 gauge syringe and protein was collected after 
centrifugation to remove cellular debris. 30-60µg of protein was electrophoresed onto a 
SDS-PAGE gel. The protein was transferred to a nitrocellulose membrane using a 
semidry apparatus (BioRad). The membrane was blocked using 5% milk in TBST and 
incubated in either 5% milk in TBST or 5% bovine serum albumin (BSA) in TBST.  
Membranes were incubated with the appropriate secondary antibodies conjugated to 
horseradish peroxidase (HRP) at concentrations of 1:5000 in 5% milk in TBST. Protein 
bands were detected by electrochemiluminescence. 
Microarray Methods 
RNA was isolated from MCF10A, MD-MBA-231, and SUM-149 cell lines grown 
with or without ZA treatment using Trizol according to the instructions.  RNA was 
cleaned using the RNAeasy MinElute Cleanup Kit (Qiagen) according to instructions, 
and submitted to the University of Michigan Microarray Core.  One experiment was done 
in duplicate.  Expression values for each gene were calculated using the robust multi-
array average method [108] .  Only probesets with a 2 fold or higher change (when ZA 
treated cells were compared to untreated cells) were selected for comparison across the 




Quantitative RT-PCR methods 
RNA was isolated from cell lines grown with or without ZA treatment using 
Trizol.  The Promega Reverse Transcription System was used according to package 
instructions to make cDNA from isolated RNA.  SYBR Green Mastermix was used 
according to directions for Quantitative PCR.  Three experiments were done in triplicate. 
Preparation of Extracts for Targeted Metabolomics and 13C mass isotopomer analysis 
Cell extracts were prepared and analyzed according to a modified protocol from 
Lorenz et al, [118]. Cells were grown to 80% confluence on 6 cm culture plates.  Cells 
were then changed to XF Assay Medium Modified DMEM (Seahorse Biosciences) 
supplemented with 11 mM glucose and 10 mM pyruvate or Dulbecco's Modified Eagle’s 
Medium (DME) Base without L-Glutamine, Glucose, Phenol Red, Sodium Pyruvate, or 
Sodium Bicarbonate supplemented with 11mM glucose and 10 mM sodium pyruvate, 2.5 
mM glutamine and .015g/L phenol red and incubated at 37°C for 1 hour in a non-CO2 
incubator.  Cells were then changed to the same media with uniformly labeled 13C-
glutamine or 13C-2,3 pyruvate and incubated for the indicated 15 minutes. Cells were 
then rinsed by rapid addition and removal of 3 mL of distilled water, after which 
metabolism was immediately quenched by pouring liquid nitrogen into the plate.  Plates 
were stored at -80°C until extraction.  Cells were extracted by adding 500 µL of ice-cold 
8:1:1 methanol:water:chloroform to the frozen cell surface and scraping with a cell 
scraper. The extract and residual cell debris were transferred to polypropylene 
microcentrifuge tubes and centrifuged for 5 min at 15,000 x g at 4°C.  The supernatant 




LC-MS Methods and Data Analysis 
For targeted metabolomics and 13C mass isotopomer analysis, samples were 
analyzed on an Agilent 1200 LC / 6520 qTOF MS system.  To obtain good retention of 
the polar, predominantly anionic metabolites of glycolysis and the TCA cycle, 
chromatographic separation was performed by mixed mode hydrophilic interaction – 
anion exchange using a Luna NH2 3µ column, 150 mm x 1 mm ID (Phenomenex, 
Torrance, CA).  Mobile phase A was acetonitrile and mobile phase B was 5 mM 
ammonium acetate in water, adjusted to pH 9.9 using ammonium hydroxide.  The 
gradient was a 15 minute linear ramp from 20 to 100%B, followed by a 5 minute hold at 
100%B and a 17-minute requilibration period at 20%B.  The column temperature was 
25°C and the flow rate was 0.07 mL/min, which was ramped to 0.09 mL/min between 20 
to 32 minutes.  The injection volume was 10 µL.  Electrospray ionization was carried out 
in negative ion mode using a source gas temperature of 350° C, a drying gas temperature 
of 10 L/min, a nebulizer pressure of 20 psig, and a capillary voltage of 3500 V.  Data 
were collected in TOF full-scan mode over m/z 50-1200 at an acquisition rate of 1 
spectra/s with reference mass correction enabled.  Data were analyzed using Masshunter 
Quantitative Analysis software.  Metabolites and their 13C isotopes were identified by 
retention time and m/z values determined from authentic standards.  Quantification was 
performed by peak area after manual inspection of integration accuracy. 
Protein Normalization of Mass Spectrometry Data 
Three additional plates were grown up in each experiment per cell line.  Cells 
were rinsed twice with cold PBS, and then treated with RIPA buffer with complete 
protease inhibitor cocktail (Roche) added at recommended concentrations for 5 minutes 
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with gentle agitation at 4°C.  Protein was scraped off the plate and sheared with a 23-
gauge syringe 3-4 times.  Protein was collected in microcentrifuge tubes and spun for 15 
minutes at 13,000 rpm at 4°C to pellet cellular debris.  A Bradford was performed to 
quantify the amount of protein in each sample.  This data was averaged and used to 
normalize the mass spectrometry data to account for differences in the growth rate of 
cells. 
Bioenergetic Profiles (BEP) and Extracellular Acidification Rate (ECAR) Measurements 
Cells were trypsinized and seeded with 100 µL fresh growth media into 24 well 
plates.  After 1 hour of incubation, an additional 150 µL of media was added.  The day of 
the experiment, media was replaced with XF Assay Medium Modified DMEM (Seahorse 
Biosciences) supplemented with 11 mM glucose and 10 mM pyruvate or Dulbecco's 
Modified Eagle’s Medium (DME) Base without L-Glutamine, Glucose, Phenol Red, 
Sodium Pyruvate, or Sodium Bicarbonate supplemented with 11mM glucose and 10 mM 
sodium pyruvate, 2.5 mM glutamine and .015g/L phenol red.  Cells were incubated in a 
37°C non-CO2 for 1 hour before being used for experiments.  Oligomycin, FCCP, and 
rotenone were used to achieve final concentrations of 1uM, 300 nM, and 100 nM 
respectively in the cell.  Galactose, when present, was at 11 mM final concentration.  All 
experiments were done in XF-24 Machine (Seahorse Biosciences) 
Quantitative-RT-PCR arrays 
Quantitative-RT-PCR arrays were purchased from Qiagen.  RNA was isolated using 
RNeasy Mini Kit (Qiagen) and cDNA was made using RT2 First Strand Kit (Qiagen) 








Figure V.1: MAT2A is a target of ZA 
MAT2A Western Blot B. MAT2A Model  
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MCF-10A   MDA-MB-231   SUM149












Table V.1: List of other targets identified in ZA microarray 




List of Validated ZA Targets
A
B
List of ZA targets regulated in opposing directions
Symbol Name         MDA-MB-231 SUM 149
THBS1 thrombospondin 1       DOWN  UP
ENY2  enhancer of yellow 2 homolog     DOWN  UP
PDLIM2 PDZ and LIM domain 2      DOWN  UP
CDK6  cyclin-dependent kinase 6      DOWN  UP
RIMKLB ribosomal modification protein rimK-like family member B  DOWN  UP 
PDLIM7 PDZ and LIM domain 7      DOWN  UP
NFYA  nuclear transcription factor Y, alpha    DOWN  UP
GFPT1 glutamine--fructose-6-phosphate transaminase 1  UP   DOWN
TRIB3  tribbles homolog 3       UP   DOWN
C5orf41 chromosome 5 open reading frame 41    UP   DOWN
VEGFA vascular endothelial growth factor A    UP   DOWN
JDP2  Jun dimerization protein 2       UP   DOWN
N4BP2L2 NEDD4 binding protein 2-like 2      UP   DOWN
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 UP   DOWN
MALAT1 metastasis associated lung adenocarcinoma transcript 1 UP   DOWN
NEAT1 nuclear paraspeckle assembly transcript 1    UP   DOWN
CTH  cystathionase (cystathionine gamma-lyase)    UP   DOWN
TXNIP thioredoxin interacting protein      UP   DOWN
KLHL24 kelch-like 24        UP   DOWN
GART  phosphoribosylglycinamide formyltransferase   UP   DOWN
BHLHE40 basic helix-loop-helix family, member e40    UP   DOWN
Symbol   Name
IL24    interleukin 24
TMEM45A   transmembrane protein 45A
EREG   epiregulin
AHNAK2   AHNAK nucleoprotein 2
NAV3   neuron navigator 3





Figure V.2: SUM 149 cells do not have a defect in mitochondrial pyruvate transport 
Stable isotope tracer experiments with 13C-2,3-pyruvate measuring peak intensity area under the curve of 
the following metabolites A. Lactate B. Citrate/Isocitrate C. Acetyl-CoA D. Malate E. 2 
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Table V.2: Media used in isotope tracer experiments and oxidative phosphorylation measurements 
may have had low glutamine 
Actual concentration of glutamine in media was much lower than expected 2.5 mM 
  
Expected and Measured Glutamine Concentration in Media used for
13C-2,3-Pyruvate Stable Isotope Tracer Experiments
Cell Line  Actual Glutamine Concentration Expected Glutamine Concentration
MCF-10A   0.013 ± 0.012 mM     2.50 mM  
MDA-MB-231  0.017 ± 0.006 mM     2.50 mM





Figure V.3: Oxidative phosphorylation defect in SUM149 cells is glutamine independent 
The addition of glutamine to the media does not induce SUM149 cells to undergo oxidative 
phosphorylation. A. Bioenergetic profiles measuring oxidative consumption rate (OCR) B. Extracellular 
acidification rate (ECAR).  
A
B
Oligomycin        FCCP              Rotenone
Oligomycin        FCCP              Rotenone
SUM 149 without glutamine





Figure V.4: Stable isotope tracer experiments using uniformly-labeled 13C-Glutamine 
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Table V.3: Mitochondrial Genes found to be significantly different in SUM149 cells 
A. SUM149 cells compared to MCF-10A cells.  B. SUM149 cells compared to MDA-MB-231 cells. 
  
Fold change of significant genes in SUM 149 cells compared to MCF-10A cells
A 
B 
Fold change of significant genes in SUM 149 cells compared to MDA-MB-231 cells
Symbol Name            Fold Change
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2             260.43
ATP6V1E2 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2      7.83
COX6C cytochrome c oxidase subunit Vic         6.02
ATP5J2 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2    5.22
HPRT1 hypoxanthine phosphoribosyltransferase 1        5.11
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q reductase) 4.73
SDHA  succinate dehydrogenase complex, subunit A, flavoprotein (Fp)     4.24
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase) 4.08
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa    3.74
ACTB  actin, beta            3.59
ATP5I  ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E    3.50
ATP6V1G3 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3      3.53
NDUFA11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7kDa    3.42
COX7B cytochrome c oxidase subunit VIIb         3.35
ATP5L  ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G    3.30
SDHB  succinate dehydrogenase complex, subunit B, iron sulfur (Ip)     3.29 
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa    3.12
UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI      3.01
Symbol Name            Fold Change
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2      17.70 
ATP6V1E2 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2       3.11
COX6B1 cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous)     -3.20
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa (NADH-coenzyme Q reductase) -3.42
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa     -3.79
B2M  beta-2-microglobulin           -4.06





Figure V.6: MDA-MB-231 p38γ knockdown cells display increased oxidative capacity 
Difference in oxidative capacity between MDA-MB-231 scrambled control cells and MDa-MB-231 p38γ 
knockdown cells was found to be statistically significant (p-value < 0.05) A. Bioenergetic profiles 
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